It is made available under a CC-BY 4.0 International license .

¹ Graphical Abstract

- 2 Integrating Mendelian randomization and literature-mined evidence for breast
- **3 cancer risk factors**
- ⁴ Marina Vabistsevits, Tim Robinson, Ben Elsworth, Yi Liu, Tom R Gaunt



It is made available under a CC-BY 4.0 International license .

Integrating Mendelian randomization and literature-mined evidence for breast cancer risk factors

Marina Vabistsevits^{a,b,d}, Tim Robinson^{a,b}, Ben Elsworth^{a,b,c}, Yi Liu^{a,b}, Tom R
 Gaunt^{a,b}

^aMedical Research Council Integrative Epidemiology Unit at the University of Bristol, University of Bristol, Oakfield 7 House, Oakfield Grove, Bristol, BS8 2BN, UK
 ^bPopulation Health Sciences, Bristol Medical School, University of Bristol, Oakfield 7 House, Oakfield Grove, Bristol, BS8 2BN, UK
 ^cOur Future Health, 2 New Bailey, 6 Stanley Street, Manchester, M3 5GS, UK
 ^dUniversity of Exeter Medical School, University of Exeter St Luke's Campus, 79 Heavitree Rd, Exeter, EX2 4TH, UK

^e corresponding author: Marina Vabistsevits (marina.vabistsevits@bristol.ac.uk)

9 Abstract

Objective: An increasing challenge in population health research is efficiently 10 utilising the wealth of data available from multiple sources to investigate disease 11 mechanisms and identify potential intervention targets. The use of biomedical 12 data integration platforms can facilitate evidence triangulation from these differ-13 ent sources, improving confidence in causal relationships of interest. In this work, 14 we aimed to integrate Mendelian randomization (MR) and literature-mined evi-15 dence from the EpiGraphDB biomedical knowledge graph to build a comprehen-16 sive overview of risk factors for developing breast cancer. 17

Methods: We utilised MR-EvE ("Everything-vs-Everything") data to identify candidate risk factors for breast cancer and generate hypotheses for potential mediators of their effect. We also integrated this data with literature-mined relationships, which were extracted by overlapping literature spaces of risk factors and breast cancer. The literature-based discovery (LBD) results were followed up by validation with two-step MR to triangulate the findings from two data sources.

Results: We identified 129 novel and established lifestyle risk factors and molecular traits with evidence of an effect on breast cancer, and made the MR results available in an R/Shiny app (https://mvab.shinyapps.io/MR_ heatmaps/). We developed an LBD approach for identifying potential mechanistic intermediates of identified risk factors. We present the results of MR and literature evidence integration for two case studies (childhood body size and HDLocholesterol), demonstrating their complementary functionalities.

31 *Conclusion:* We demonstrate that MR-EvE data offers an efficient hypothesis-

It is made available under a CC-BY 4.0 International license .

- 32 generating approach for identifying disease risk factors. Moreover, we show that
- ³³ integrating MR evidence with literature-mined data may be used to identify causal
- ³⁴ intermediates and uncover the mechanisms behind the disease.
- 35 Keywords: mendelian randomization, genome-wide association study, causal
- ³⁶ inference, breast cancer, literature-based discovery, knowledge graph, literature
- 37 mining

38 1. Introduction

Triangulation, a process of integrating evidence from multiple methodologies, 39 has become increasingly important in population health research [1, 2]. Differ-40 ent evidence sources are likely to have unique and unrelated sources of bias, so 41 consistent evidence from such sources improves confidence in the causal relation-42 ship between a risk factor and outcomes of interest [3]. A potential obstacle to the 43 widespread adaptation of triangulation in epidemiological research is the challenge 44 of integrating and harmonising the large volume of data from different datasets. 45 Multiple platforms [4, 5, 6, 7] have been developed to facilitate access to com-46 bined and curated biomedical datasets. Using these data integration platforms will 47 facilitate the study of disease aetiology. 48

EpiGraphDB (https://epigraphdb.org) [4] is a biomedical knowledge
graph that was designed to facilitate data mining of epidemiological relationships.
The unique advantages of this platform are the availability of both Mendelian randomization (MR) [8, 9] and literature-mined relationships between molecular and
lifestyle traits and disease outcomes, providing a valuable combination of data to
systematically investigate causal relationships.

MR is an approach to causal inference that uses genetic variants as instru-55 mentable variables (IVs) to infer whether a modifiable health exposure influences 56 a disease outcome [8]. Studying disease causality with MR methods has been 57 growing in popularity over the past decade and a half [9, 10], with the increasing 58 availability of data from genome-wide association studies (GWAS) [11, 12] and 59 well-developed analysis frameworks [13]. EpiGraphDB provides access to MR-60 EvE (Mendelian randomization "Everything-vs-Everything") pairwise causal esti-61 mates [14] between thousands of traits from the OpenGWAS database (https: 62 //gwas.mrcieu.ac.uk) [11]. MR-EvE data can be used to explore poten-63 tial causal links between thousands of traits for knowledge discovery or hypothesis 64 generation. 65

Another aspect of knowledge discovery is extracting data from the biomedical literature, also known as literature-based discovery (LBD) [15]. In addition to MR-EvE, EpiGraphDB also contains literature-mined relationships extracted from

It is made available under a CC-BY 4.0 International license .

- ⁶⁹ publications in PubMed [16] and mapped to specific phenotypes in the MR-EvE
 ⁷⁰ data. LBD entails connecting information that is explicitly stated in multiple pub-
- lications across different research disciplines aiming to deduce connections that
 have not been explicitly stated [17, 18], offering the potential to identify mechanis-
- tic pathways or mediators for causal relationships identified using MR-EvE.
- In this work, we use EpiGraphDB to build a comprehensive picture of the aeti-74 ology of breast cancer by combining evidence from MR and literature-mined data. 75 Breast cancer is a useful exemplar, as it is a heterogeneous disease with a complex 76 aetiology, affected by both genetic and lifestyle factors [19, 20, 21, 22] that also 77 has a large body of published research evidence, suitable for data mining. We seek 78 to generate new mechanistic hypotheses for causal relationships using evidence in-79 tegration to inform prevention and intervention strategies that could reduce disease 80 burden. 81
- 82

83 Statement of Significance

Problem or Issue	Limited integration of multiple sources of evidence to enhance causal inference and identify mechanisms in epidemiological re- search
What is already known	While MR studies are abundant, few utilise complementary biomedical data sources to enhance causal evidence or generate new hypotheses for underlying mechanisms
What this paper adds	By utilising MR-EvE and literature-mined data in EpiGraphDB, this study introduces a systematic, integrated approach for causal inference, applied to breast cancer risk factors. It demonstrates how combining MR and LBD enhances the identification of mediating traits, providing a model that can be applied to other complex dis- eases

84 2. Methods

85 2.1. Study Design

We present a summary of our EpiGraphDB data-focused study in Figure 1. First, we explored MR-EvE causal estimates between various exposure traits and breast cancer to generate a list of potential causal risk factors and biomarkers. Then, we used literature-mined relationships from EpiGraphDB to dissect the risk factor/breast cancer relationships. We designed an LBD method for overlapping literature spaces of traits to identify potential intermediates between individual traits and breast cancer.

We demonstrate evidence integration between MR and LDB on two case study breast cancer risk factors: *childhood body size* and *HDL-cholesterol*. We queried

It is made available under a CC-BY 4.0 International license .

⁹⁵ MR-EvE data using a two-step MR approach [23, 24] to identify potential medi-

⁹⁶ ators (i.e. traits affected by each risk factor that in turn affect breast cancer risk).

⁹⁷ We also determined potential intermediates using LBD and evaluated them using

98 MR and data from OpenGWAS. In this way, we triangulated evidence for the iden-

⁹⁹ tified mediators from two independent data sources. Analysis code is available at

100 https://github.com/mvab/epigraphdb-breast-cancer and https:

101 //github.com/mvab/epigraphdb_mr_literature_queries.

102 2.2. EpiGraphDB

EpiGraphDB (https://epigraphdb.org) is a graph database that inte-103 grates biomedical and epidemiological data, built to support data mining of risk 104 factor/disease relationships. It contains trait relationships (observational and ge-105 netic), literature-mined relationships, biological pathways, protein-protein interac-106 tions (PPIs), drug-target relationships and other data sources [4]. EpiGraphDB is 107 integrated with the OpenGWAS database data [11] (https://gwas.mrcieu. 108 ac.uk), providing access to GWAS studies via the GWAS node of the graph. 109 The number of GWAS studies in OpenGWAS at the time of writing is 50,040; of 110 these, 34,494 are integrated within EpiGraphDB. EpiGraphDB (version 0.3.0) was 111 accessed via R package *epigraphdb-r* (version 0.2.3). 112

113 2.3. Breast cancer data

EpiGraphDB provides access to multiple breast cancer GWAS datasets de-114 posited in OpenGWAS. We used the most recent releases of the Breast Cancer As-115 sociation Consortium (BCAC) (http://bcac.ccge.medschl.cam.ac.uk/) 116 meta-analyses conducted in 2017 (BCAC 2017, N=228,951) [25] and 2020 (BCAC 117 2020, N=247,173) [26]. Since only BCAC 2017 is available in EpiGraphDB/OpenGWAS, 118 this dataset was used for the MR-EvE risk factor discovery analysis. Both BCAC 119 2017 and 2020 were utilized for the validation stage. In addition to the overall sam-120 ple, the datasets contain the ER+ and ER- sub-samples and five molecular subtypes 121 (Supplementary Table 1). The study groups in the BCAC cohort do not include UK 122 Biobank or other trait cohorts used in this study. The cohort includes European-123 ancestry individuals only. 124

125 2.4. Mendelian randomization and MR-EvE data

MR is an application of instrumental variable analysis where genetic variants are used as proxies (genetic instruments) to estimate the causal relationship between a modifiable health exposure and a disease outcome [8, 9]. MR-EvE (MR "Everything-vs-Everything") data is stored as bidirectional relationships between GWAS traits in EpiGraphDB, available for 11,789 GWAS traits at the time of writing. The MR-EvE estimates were generated using the MR Mixture-of-Experts

It is made available under a CC-BY 4.0 International license .



Figure 1: **Study overview**. Employing EpiGraphDB, MR-EvE data was used to identify breast cancer risk factors, and literature-mined data was used to design a literature-based discovery (LBD) method for identifying potential intermediates between risk factors and breast cancer. For two case studies, we present evidence integration between MR-EvE-guided and LBD-identified potential mediators. Abbreviations/definitions: MR-EvE – Mendelian Randomization "Everything-vs-Everything"; Exp – exposure; Med – mediator; Out – outcome; BCAC – Breast Cancer Association Consortium (refers to meta-analyses breast cancer cohort GWAS data); literature space – a collection of literature-mined relationships between pairs of biological terms related to a phenotype.

- (MR-MoE) method by Hemani *et al* [14] before integration into EpiGraphDB. MR-
- ¹³³ MoE is a machine learning framework that automated the selection of instrument
- ¹³⁴ SNPs and the MR method for use in any specific causal analysis by predicting
- the model of pleiotropy and relating that prediction to the most appropriate model

It is made available under a CC-BY 4.0 International license .

- [14]. The method selects the MR 'best estimate' of causal relationships betweenthe exposures and the outcome traits.
- The interconnection of many traits in the MR-EvE data makes it a valuable resource for identifying potential mediators and confounders [27] for a causal relationship of interest (https://epigraphdb.org/confounder) [4]. In this work, we make use of this functionality to generate hypotheses for breast cancer risk factors and potential mediators.
- 143 2.5. Identifying breast cancer risk factor traits from MR-EvE

144 2.5.1. Discovery

We queried EpiGraphDB to extract MR-EvE results for all available GWAS traits (N = 2218, Supplementary Table 2) with breast cancer as the outcome. Figure 2 summarises the discovery and validation stages of the analysis. The initial set of traits linked to breast cancer with any MR estimate was reduced to traits that passed False Discovery Rate (FDR), taking traits with the corrected p-value < 0.05 (N = 378) into the downstream analysis (Figure 2).

The traits were grouped into 12 categories, which included widely-known cancer risk factor categories (anthropometric traits, reproductive traits, physical activity, smoking, alcohol), categories with a growing research interest (dietary intake traits, sleep traits, medication), and molecular traits (metabolites, lipids, proteins, and other biomarkers) (N = 202). The traits outside of these categories were grouped as 'Other' and excluded. The full data from the discovery stage is available in Supplementary Table 3.

158 2.5.2. Validation

The results of the MR-EvE rapid screen of risk factors were validated by reanalysing the identified relationships using the robust practices in two-sample MR [28], because MR-EvE 'best estimates' selected by the MR-MoE method do not always correspond to the standard methods used in MR studies [14]. The validation results in this study are reported as per the STROBE-MR guidelines [29, 30].

For the majority of exposure traits, instruments were extracted using the genome-164 wide approach, i.e. SNPs with p-value $< 5 \times 10^{-8}$ and clumped with $r^2 < 0.001$ 165 using 1000 Genomes European LD reference panel. For protein traits, *cis*-region 166 instruments were prioritised (within 1Mb on either side of the protein-encoding 167 gene) [31]. The extracted *cis*-SNPs were filtered to p-value $< 5 \times 10^{-8}$ or a less 168 stringent 'local' threshold of p-value < 0.05/nSNPs, where nSNPs is the number 169 of SNPs in the *cis* region. The clumping was done using $r_2 < 0.01$, or $r_2 < 0.001$ 170 if the higher threshold produced ≥ 7 SNPs. If no instruments were available under 171 these criteria, genome-wide extraction of instruments was applied. The details of 172

It is made available under a CC-BY 4.0 International license .



Figure 2: MR-EvE evidence processing workflow, including Discovery and Validation stages. The boxes show the number of exposures (pink) and breast cancer outcomes (blue) after/in each filtering step; MR-EvE results validation Shiny app: https://mvab.shinyapps.io/MR_heatmaps/. BCAC - Breast Cancer Association Consortium

instrument extraction for protein traits are provided in Supplementary Tables 4 and5.

The validation analysis was performed on breast cancer molecular subtypes data (BCAC 2020) in addition to the overall sample and ER+/ER- subtypes (BCAC 2017). The inverse-variance weighted (IVW) [32] approach was used as the main two-sample MR method. To correct for multiple testing in the validation step, the FDR cut-off of 0.05 for the corrected p-value was applied to identify results with

It is made available under a CC-BY 4.0 International license .

¹⁸⁰ more robust evidence of effect (Supplementary Table 4) (Figure 2).

To investigate potential violations of the MR assumptions and validate the ro-181 bustness of MR results, additional analyses were performed. This included pleiotropy-182 robust sensitivity analyses such as MR-Egger [33] and weighted median [34]. The 183 Egger intercept test [33] was used to test for directional horizontal pleiotropy, and 184 Cochran's Q statistic [35] was calculated to quantify heterogeneity among SNPs, 185 which is indicative of potential pleiotropy. F-statistic was used to assess instrument 186 strength [36] (Supplementary Tables 4 and 6). Sensitivity analysis results were not 187 used for additional filtering of all identified risk factor traits to avoid information 188 loss due to dichotomisation [37], but were taken into account when evaluating in-189 dividual traits. Additionally, the sensitivity results were included in the MR results 190 heatmap visualisation to provide context on the performance in sensitivity tests for 191 all traits. All MR and sensitivity analyses were performed using the *TwoSampleMR* 192 R package (version 0.5.6) [13]. 193

194 2.6. Using literature-mined relationships in EpiGraphDB

EpiGraphDB contains literature-mined relationships between pairs of terms 195 (also known as 'literature triples') derived from the published literature [38]. The 196 underlying literature data comes from SemMedDB (Semantic MEDLINE Database) 197 [16], a well-established repository of literature-mined semantic triples, i.e. 'subject 198 term 1 – predicate – object term 2', mined from titles and abstracts of nearly 30 199 million biomedical articles in PubMed, using SemRep [39, 40] (further details are 200 available in Appendix A). A subject/object term can be any biological entity (gene 201 name, drug, phenotype, disease); a predicate is a verb that represents a relationship 202 between the two terms (affects, causes, inhibits, reduces, associated with, etc.). 203

204 2.6.1. Literature space

Literature triples of biomedical terms are mapped to specific GWAS traits in 205 EpiGraphDB. In this work, we introduce the concept of a 'literature space'. The 206 literature space for a trait (e.g. breast cancer) comprises a set of semantic triples 207 extracted from the published literature for this trait. Literature space can be consid-208 ered an 'automated literature overview' of conceptual relationships between bio-209 logical entities related to the search term, i.e. breast cancer. In the literature space, 210 each relationship triple has a score that indicates how frequently it occurs in the 211 published literature within a defined time frame (linked to PubMed IDs), demon-212 strating how well-established this relationship is. 213

214 2.6.2. Literature spaces overlap method

In the field of LBD, the underlying principle of working with triple-based literature data is known as Swanson linking [41, 42]. In this approach, two separately

It is made available under a CC-BY 4.0 International license .

published results (e.g. A-B and B-C relationships) are combined to identify evidence for the A-C relationship that is unknown or unexplored. The discovery can
be open and closed: in open, A is given to identify Bs linked to Cs, generating hypotheses; in closed, A and C are fixed, and Bs that link them are identified, testing
hypotheses or finding intermediates [43, 18] (details in Appendix A).

In this work, we present an extension to the simple triple linking method used 222 in MELODI-Presto [38], which focused on the overlap of two triples (i.e. A-B 223 and B-C only) (3a). Here, we combine multiple triples from two literature spaces 224 (exposure trait and breast cancer) into a so-called 'literature overlap'. We apply 225 multi-step triple linking within and between the literature spaces to generate hy-226 potheses for the potential mediators of the exposure trait's effect on breast cancer. 227 The literature data pre-processing steps and the method details are provided in Ap-228 pendix A. The overview of our LBD method is presented in Figure 3, including 229 closed (3b) and open (3c) discovery, and an example application (3d). 230

231 2.7. MR and literature evidence integration

We integrated the evidence from MR-EvE and literature mining for potential mediators of two breast cancer risk factors that we selected as case studies: *childhood body size* and *HDL-cholesterol*.

235 2.7.1. Potential mediators from MR-EvE data

We queried the MR-EvE data to identify potential mediators of each case study risk factor using the two-step MR framework [23, 24, 44]. The mediator search results were corrected for multiple testing using FDR at the individual case study level, for each step within two-step MR: (*step 1*) a risk factor trait effect on potential mediators, and (*step 2*) potential mediators' effects on breast cancer outcomes (BCAC 2017 data only).

The mediators passing the FDR-adjusted p-value < 0.05 filtering in both steps and restricted to the earlier specified 12 trait categories were taken into the validation step. The validation for two-step MR results included the same analysis and sensitivity methods used for the main risk factors (2.5.2). The validated two-step MR estimates were also corrected for FDR.

247 2.7.2. Potential mediators from the LBD literature overlap approach

The literature spaces for risk factor traits and breast cancer were constructed using the literature data linked to the following GWAS traits: breast cancer (combination of two traits: '*breast cancer*' - *ieu-a-1126* and '*malignant neoplasm of the breast*' - *finn-a-C3_BREAST*), HDL ('*HDL-cholesterol*' - *ukb-d-30760_irnt*), childhood body size ('*childhood obesity*'- *ieu-a-1096*) (Supplementary Tables 14-15).

It is made available under a CC-BY 4.0 International license .



Figure 3: Schemas of the literature-based discovery method, demonstrating the approach behind literature spaces overlap. (a) A basic example of linking two triples via an overlapping term. (b) Closed discovery: overlap of two traits' literature spaces (blue - risk factor, orange - breast cancer) by chaining triples of terms between them. The outer terms are restricted ('i.e. 'anchored') to the term representing the trait (T: trait) and the term representing breast cancer outcome (BC: breast cancer). All intermediate terms are arbitrarily named A-F. The arrows represent all possible paths from T to BC, which are alternatives to the full path going through all intermediates. Closed discovery is applied to molecular traits. (c) Open discovery: Applied to non-molecular/lifestyle traits, where the trait is not available as a term and therefore cannot be anchored. The unlinked triples in the non-molecular trait space are first matched (via term B) to link with any triples in the breast cancer space. Then, the linked triples are connected to other triples in the non-molecular trait space (via term A), expanding the literature spaces overlap. (d) Example of literature spaces overlap visualisation: Sankey diagram showing how triples within and between a risk factor trait (here, cardiotrophin-1) and breast cancer spaces interconnect. The line width of each term relationship indicates how common it is in the literature (frequency score). Cardiotrophin-1 is presented here as an example. More examples, specifically the case study traits in this study, are available to view at https://mvab.shinyapps.io/literature_overlap_sankey/

It is made available under a CC-BY 4.0 International license .

In the literature overlap generated from triples in the risk factor trait and breast cancer literature spaces, all intermediate biological terms were evaluated as potential mediators. Each term was searched in OpenGWAS for representative GWAS data to be used in MR analysis, and genetic instruments for the identified traits were extracted as previously described (2.5.2).

We performed MR bidirectionally between the risk factor trait and each intermediate to identify the direction of effect, as it may not be correct in literaturemined relationships. Then, the intermediate traits were evaluated for an effect on breast cancer. The results were validated using the analysis and sensitivity methods described previously (2.5.2), and adjusted using FDR.

The evidence in both steps of the two-step MR analysis provided suggestive evidence of potential mediation between the risk factor and breast cancer via a trait identified by the LBD method.

267 3. Results

268 3.1. Breast cancer risk factors discovered from MR-EvE

We identified 129 traits across 12 categories that showed evidence of an effect on breast cancer risk from MR-EvE data (Figure 2). The discovery effect estimates were validated using the IVW MR analysis with sensitivity analyses, using 9 breast cancer outcome GWAS from two releases of BCAC data. The instruments were extracted as described in 2.5.2. To correct for multiple testing of many exposures and outcomes in the validation step, the FDR correction was applied. The validation results and sensitivity analyses are available in Supplementary Tables 4 and 6.

The MR results for the final set of traits (129 traits or 63 after FDR correc-276 tion) are presented in Figure 4. The figure also provides an overview of sensi-277 tivity analysis results: potential pleiotropy "P", heterogeneity "H", and "X" for 278 exposures with a low number of instruments (≤ 2) where most sensitivity tests 279 were not possible. The full results (202 traits) are available in the R/Shiny app 280 (https://mvab.shinyapps.io/MR_heatmaps/) and Supplementary Ta-281 ble 4. The abbreviations for traits/biomarkers used throughout the section are de-282 fined in Supplementary Table 7. In the sections below, the results of several trait 283 categories are summarised. 284

285 3.1.1. Non-molecular traits

The majority of anthropometric traits (e.g. *body mass index, obesity, waist-tohip ratio, childhood body size*) (Figure 4a) have consistent inverse (risk-decreasing) effects across most breast cancer subtypes. Interestingly, *impedance of whole body* has a positive (risk-increasing) effect on most outcomes, potentially capturing a

It is made available under a CC-BY 4.0 International license .



Figure 4: Mendelian randomization effect direction heatmaps for (A) lifestyle and anthropometric traits, (B) metabolites and lipids, (C) proteins (N=129) as exposures, and breast cancer (BCAC 2017 and 2020 overall samples and subtypes) as the outcomes. The presented traits have evidence of an effect on at least one outcome, but the full set of traits analysed in the validation step (N=202) is available in the interactive version of the plot in the app: https://mvab.shinyapps.io/MR_heatmaps/ and in Supplementary Table 4. [continued on the next page]

It is made available under a CC-BY 4.0 International license .

Figure 4: [continued] The proportions of the total size of each group displayed here are: Anthropometric – 95%, Lifestyle – 57%, Lipds -100%, Metabolites – 68%, Proteins – 54%. The colours represent effect direction: pink – positive (causal), green – negative (protective), white – null effect (based on 95% CIs of odds of breast cancer per standard deviation increase in the exposure). The darker colour shade indicates the results that passed the FDR correction. The letters summarise arbitrarily dichotomised sensitivity analysis results: "P" - potential pleiotropy (*abs*(egger intercept)>0.05); "H" - heterogeneity (Q-stat p-value < 0.05); "X" - low number of instruments (≤ 2) where sensitivity analyses were not possible; an empty cell indicates that no H/P/X issues were identified. For proteins, where possible, *cis*-only instruments were used (marked with an asterisk *). The proteins were grouped by major pathways defined in the Reactome database [45] for display purposes. Proteins are displayed by the encoding gene name (defined in Supplementary Table 7). The exposure traits are from mixed-sex samples unless otherwise specified (F: female-only) or are female-specific reproductive traits. The details on breast cancer outcome samples are provided in Supplementary Table 1.

different aspect of adiposity. The traits in this group show evidence of high instrument heterogeneity ('H' in Figure 4a) based on the arbitrary threshold used (Q-stat p-value < 0.05). This indicates the complexity of these phenotypes, suggesting that multiple underlying mechanisms are likely involved. Evaluating multiple related/correlated phenotypes is acceptable, as none of them are perfect measures of adiposity, and they likely proxy adiposity in different ways, e.g. BMI (subcutaneous fat) vs waist-hip ratio (central adiposity).

Among physical activity traits (UK Biobank traits based on a survey question 297 "Types of physical activity in last 4 weeks"), 'Heavy DIY' shows evidence of a 298 protective effect in overall samples (with little indication for heterogeneity and 299 pleiotropy). Among dietary traits, there is a protective effect from 'dried fruit in-300 take' on outcomes with larger sample sizes. The intake of processed/sugary break-301 fast cereals (i.e. Frosties, Cornflakes) appears to have a risk-increasing effect, but 302 the instruments here are also likely highly pleiotropic as is commonly seen for di-303 etary intake traits. The important considerations for dietary and physical activity 304 exposures in MR analyses are addressed in Appendix C. 305

The '*never smoked*' phenotype appears to confer a decreased risk in selected breast cancer subtypes. '*Chronotype (evening preference)*' shows evidence of increasing the risk in outcomes with larger sample sizes. '*Snoring*' also has a causal effect on some outcomes. Higher *age at menopause* has a risk-increasing effect on most outcomes, while '*Had menopause*' phenotype (potentially capturing earlier menopause) is protective.

312 3.1.2. Molecular traits

The lipid traits have a distinct effect direction pattern (Figure 4b): a consistently positive (causal) effect from HDL particle measures and a negative (protective) effect from VLDL. For all, there is limited evidence of effect on ER- breast

It is made available under a CC-BY 4.0 International license .

cancer and several molecular subtypes. It should be noted that LDL measures
were also available in the MR-EvE discovery data, (i.e. 2218 traits), but did not
pass filtering thresholds in the validation step due to weak evidence of effect (data
available in Supplementary Table 3). Among other metabolites (Figure 4b), 3dehydrocarnitine, betaine, and X-11440 show the strongest evidence of a negative
effect on breast cancer risk.

The proteins with the most robust evidence (FDR-adjusted p-value < 0.05 and based on *cis*-instruments only) are IL1RL1, ISLR2, SAT2 (negative effect) and PRTN3, B3GNT2, CPXM1, PLXNB2 (positive effect). The proteins that did not pass FDR correction, but are also based on *cis*-only instruments and have effect on more than one outcome, include IL6R, EREG, DCBLD2 (negative effect) and VTN, IDUA, DNAJB11, XXYLT1 (positive effect).

Among the proteins for which genome-wide instruments were used (which may be picking up horizontal pleiotropy), the most consistent evidence of effect was observed for FLNA, ADH6, CAMK1 (negative effect) and IL21, CAST (positive effect) with little heterogeneity and pleiotropy detected ('P' and 'H' not present in Figure 4c).

333 *3.2. Evidence integration case studies*

This section presents two exposure traits from the discovery of the MR-EvE 334 risk factor, childhood body size and HDL cholesterol, as case studies. Although 335 both have previously been investigated in relation to breast cancer, the underlying 336 mechanisms remain unclear. We used MR-EvE data and data mined from liter-337 ature to generate hypotheses for potential mediators and cross-validate evidence 338 from both sources. Since these traits have opposite effects on breast cancer risk 339 and represent both molecular and non-molecular risk factors, they provide a ro-340 bust framework for demonstrating open and closed literature-based discovery, sup-341 ported by large literature spaces (Appendix A). 342

343 3.2.1. Case study 1: Childhood body size

Childhood adiposity has been shown to have a protective effect on breast cancer risk in both observational [46, 47] and MR studies [48, 44], but the mechanism and mediators of this effect remain unclear. MR analysis shows strong evidence of an inverse effect from childhood body size (OpenGWAS ID: *ukb-b-4650*, female-only sample) on all breast cancer subtypes (Figure 4) (e.g. OR 0.60 [95% CI 0.53: 0.69] for BCAC 2017 overall sample).

MR-EvE mediators. In the initial MR-EvE scan, 125 putative mediators of the childhood body size effect on breast cancer were identified. Among these, several

It is made available under a CC-BY 4.0 International license .

were considered as potential mediators in earlier work [44]: IGF-1, age at menar-352 che, age at menopause, age at last birth, glucose, glycated haemoglobin (Supple-353 mentary Table 8). Following two-step MR results validation, 71 traits had evidence 354 of effect in both steps at nominal significance and 54 traits at the FDR-corrected 355 level (Supplementary Tables 9 and 10). Among these, a large proportion were adult 356 anthropometric traits (N=30). Since adult adiposity has been shown to be unlikely 357 to mediate the childhood adiposity effect [48, 49], these traits were not reviewed 358 further. Lipid traits (N=20) were also not considered further as they are unlikely to 359 mediate substantial effect individually. The remaining candidate mediators traits 360 were: exercise to keep fit (from UK Biobank physical activity questionnaire), sleep 361 duration, skimmed milk intake, and Apolipoprotein A (ApoA) (Table 1). 362

mediator	outcome	step1: beta	step1: p-value	step2: OR	step2: p-value
Apolipoprotein A ukb-d-30630_irnt	Overall BC	-0.23 [-0.28:-0.17]	2.9e-15	0.77 [0.66:0.88]	2.2e-4
Skimmed milk ukb-d-1418_3	ER+ BC	0.09 [0.08:0.11]	2.1e-35	0.01 [0:0.15]	0.0014
Exercise to keep fit ukb-a-484	Overall BC	0.02 [0.001:0.04]	0.029	0.4 [0.21:0.75]	0.0044
Sleep duration ukb-b-4424	ER+ BC	-0.04 [-0.08:-0.01]	0.0053	1.49 [1.12:2.0]	0.0071

Table 1: **Two step-MR results for potential mediators of childhood body size/breast cancer relationship, identified in a hypothesis-free way via mining MR-EvE.** The results in the table are from the MR IVW validation analysis, showing beta [95%CI] for *step 1* (the effect of childhood body size on mediator, measured as SD change in mediator per body size category change) and OR [95%CI] for *step 2* (the odds of breast cancer per SD higher mediator). The table only includes the results that passed FDR in both steps. The table does not include anthropometric and lipid traits (the full results are available in Supplementary Table 9).

Higher childhood body size shows some evidence of an increasing effect on the amount of *exercise to keep fit* in adulthood (effect size: 0.02 [95% CI 0.001: 0.04], step 1), which in turn has a protective effect on breast cancer risk (OR: 0.4 [95% CI 0.21: 0.75], step 2) (in agreement with published MR study [50] and results in 3.1.1). The relationship between childhood adiposity and the amount of exercise in adulthood has not been explored with MR designs before, so this finding warrants further follow-up.

Higher childhood body size has a negative effect on *sleep duration* in adulthood (effect size -0.04 [95% CI -0.08: -0.01], step 1), while longer sleeping time increases breast cancer risk (stronger evidence for ER+, OR 1.49 [95% CI 1.12: 2.0], step 2), in agreement with published work [51].

Literature mediators. Next, we reviewed literature-mined terms that connect childhood adiposity to breast cancer. The Sankey diagram in Supplementary Figure B.6 shows the literature overlap between the two traits (Supplementary Table 17), performed using the open discovery approach (Figure 3c, 2.6.2) (view interactively at

It is made available under a CC-BY 4.0 International license .

378 https://mvab.shinyapps.io/literature_overlap_sankey/).

The intermediate terms of the literature overlap include traits considered in earlier hypothesis-driven work [44] as potential mediators: IGF-1, testosterone, SHBG, insulin, and oestradiol. IGF-1 was also found using MR-EvE, but did not pass the FDR correction (mixed-sex sample data). The overlap contains many other literature-mined terms that make interesting mediation hypotheses (e.g. leptin, prolactin, adiponectin).

Next, to assess the identified intermediate terms as potential mediators using MR analysis, we searched OpenGWAS for suitable GWAS data to represent them. Of the 112 potential intermediate traits identified, data was available for 49, with traits having at least one SNP instrument (Supplementary Table 18).

We carried out MR bidirectionally between childhood body size (*ukb-b-4650*) and 38 potential intermediate traits (Supplementary Tables 19 and 20), followed by assessing their effect on breast cancer (Supplementary Table 21). A subset of combined results from the three MR analyses are presented in Table 2.

The criteria for a trait to have suggestive evidence of being a potential mediator (i.e. evidence of effect in *step1 forward* and *step2* (i.e. two-step MR), and preferably no effect in *step1 reverse*) was met by two traits: IGF-1 and bioavailable testosterone. These two traits have been previously evaluated in [44] two-step MR analysis, with equivalent results and sensitivity analyses.

398 3.2.2. Case study 2: HDL-cholesterol

HDL-cholesterol (HDL-C) has been shown to have a risk-increasing effect on breast cancer in several MR studies [52, 53, 54], which opposes the finding from a large meta-analysis of prospective studies that showed a modestly inverse association [55]. This makes HDL-C an interesting case study for hypothesis-free mediators search, as this may help to dissect the mechanism linking it to breast cancer.

The HDL-C trait in MR-EvE is based on mixed-sex sample data from UK Biobank (OpenGWAS ID: *ukb-d-30760_irnt*); the evidence of effect from IVW for BCAC 2017 overall sample is OR 1.09 [95% 1.04: 1.13] (no effect on certain subtypes) (Figure 4b), which is in agreement with previous studies and consistent between sensitivity analysis MR methods (Supplementary Tables 4 and 6).

MR-EvE mediators. In the initial MR-EvE scan, 102 potential mediators of HDL-C's effect on breast cancer were identified, primarily lipid traits, proteins, and anthropometric traits (Supplementary Table 11). After two-step MR validation, 60 traits showed nominal significance, and 44 remained significant after FDR correction (Supplementary Tables 12 and 13). Of these potential mediators, 36 were lipid traits, which we did not evaluate further due to their high correlation with HDL-C

It is made available under a CC-BY 4.0 International license .

Mediator trait	Step 1, forward (effect size, [95%CI])	Step 1, reverse (effect size.[95%CI])	Step 2 (OR, [95%CI])
Alanine transaminase ebi-a-GCST90013405	0.03 [0.02:0.04]*		
CRP ieu-b-35	0.39 [0.31:0.46]*		
CSNK1D prot-a-693			1.11 [1.01:1.22]
Cortisone met-a-354	-0.04 [-0.07:-0.02]*		
E selectin prot-b-77			0.95 [0.93:0.97]*
EGF prot-a-908		0.01 [0:0.02]	
FABP4 prot-b-71	0.59 [0.27:0.90]*		
Glycoprotein acetyls met-c-863	0.33 [0.20:0.45]*		
IGF-1 ukb-d-30770_irnt	-0.24 [-0.31:-0.16]*	-0.02 [-0.03:0]	1.07 [1.01:1.13]
Insulin receptor prot-a-1564			0.94 [0.92:0.97]*
IGF1R prot-a-1444			0.82 [0.76:0.88]*
Leptin receptor prot-a-1724		0.01 [0:0.01]	
Oestradiol (F) ieu-b-4872	-0.07 [-0.14:-0.01]	0.14 [0.08:0.21]*	
SHBG (F) ieu-b-4870	-0.20 [-0.29:-0.10]*		
TSHbeta levels ebi-a-GCST90010353		0.04 [0.01:0.08]	
TNFRSF11B prot-b-83			0.93 [0.87:0.99]
Bio Testosterone (F) ieu-b-4869	0.10 [0.04:0.17]*		1.12 [1.04:1.20]*
Total Testosterone (F) ieu-b-4864			1.14 [1.06:1.23]*

Table 2: Subset of MR results (bidirectional and two-step) for potential mediators of childhood body size/breast cancer relationship, identified using LBD. The table combines the results from three MR analyses: *step 1 forward* (childhood body size \rightarrow mediator trait), *step 1 reverse* (mediator trait \rightarrow childhood body size), and *step 2* (mediator trait \rightarrow overall breast cancer). '*step 1 forward*' and '*step 1 reverse*' corresponded to bidirectional MR analysis; '*step 1 forward*' and '*step 2*' together correspond to two-step MR study design. The table only shows the results that pass the threshold of p.value < 0.05; the results that pass FDR are marked with an asterisk*. The full results are available in Supplementary Tables 19, 20, 21. *Abbreviations*: CRP - C-Reactive protein, TSHbeta - Thyrotropin subunit beta, TNFRSF11b – tumour necrosis factor receptor superfamily member, CSNK1D - Casein kinase I isoform delta, EGF – epidermal growth factor, FABP4 - fatty acid binding protein 4; (F) - female-only data

and, therefore, the need for multivariable MR (MVMR) analysis. The identified
mediators also included several anthropometric traits, which may have a role in the
effect of HDL-C on breast cancer risk, but also would require further investigation
using MVMR for traits capturing different adiposity components (e.g., waist-hip
ratio, BMI).

HDL-C was found to have an increasing effect on two protein traits, ApoA (ef-

It is made available under a CC-BY 4.0 International license .

fect size: 0.87 [95% 0.84: 0.90]) and *cathepsin F* (CTSF) (0.14 [95% 0.03: 0.24]) 422 (Table 1. The relationship and interplay between HDL-C, ApoA, and cathepsins 423 have been investigated before [56, 57]. ApoA is the major protein component of 424 HDL, which has an inverse effect on breast cancer in MR (OR: 0.77 [0.66:0.88], 425 using cis-instruments only), also previously studied in connection to breast can-426 cer [58]. CTSF has a positive effect on breast cancer risk (OR: 1.14 [95% 1.08: 427 1.21], single *cis*-instrument). CTSF belongs to a class of evolutionally conserved 428 cysteine proteases involved in various biological processes that have been linked to 429 disease, including cancer progression [59, 60]. Cathepsins (F, S, K; each to various 430 degree) degrade lipid-free molecules of ApoA, leading to a complete loss of the 431 ApoA's function as a cholesterol acceptor, stopping its anti-inflammatory action 432 [56], which may be related to CTSF's role in disease. Further investigation into 433 the mechanism linking HDL-C, ApoA, and CTSF (and potentially other cysteine 434 proteases), and breast cancer is needed. 435

mediator	outcome	step 1: beta	step1: p-value	step2: OR	step2: p-value
Apolipoprotein A ukb-d-30630_irnt	Overall BC	0.87 [0.84:0.9]	0	0.77 [0.66:0.88]	2.2e-4
Cathepsin F (CTSF) prot-a-722	Overall BC	0.14 [0.03:0.24]	0.014	1.14 [1.08:1.21]	7.5e-6
Childhood obesity ieu-a-1096	Overall BC	-0.19 [-0.35:-0.03]	0.023	0.82 [0.76:0.88]	2.4e-7
Hip circumference ieu-a-51	Overall BC	-0.07 [-0.11:-0.02]	0.0043	0.73 [0.59:0.9]	0.0039
Waist circumference ieu-a-63	Overall BC	-0.07 [-0.11:-0.02]	0.0039	0.73 [0.59:0.9]	0.0039
Weight ukb-b-12039	ER- BC	-0.04 [-0.07:-0.01]	0.0062	0.87 [0.79:0.95]	0.0029
Exercise to keep fit ukb-a-484	Overall BC	0.01 [0:0.02]	0.012	0.4 [0.21:0.75]	0.0044
Snoring ukb-a-14	ER- BC	0.01 [0:0.02]	0.0015	5.83 [1.9:17.87]	0.0021

Table 3: Two step-MR results for potential mediators of HDL-cholesterol/breast cancer relationship, identified in a hypothesis-free way via mining MR-EvE. The results in the table are from the MR IVW validation analysis, showing beta [95%CI] for *step 1* (the effect of HDL-C on mediator, measured as SD change in mediator per SD higher HDL-C) and OR [95%CI] for *step 2* (the odds of breast cancer per SD higher HDL-C). The table only includes the results that passed FDR in both steps. The table does not include lipid traits (the full results are available in Supplementary Table 12).

Literature mediators. Next, we reviewed literature-mined data connecting HDL
and breast cancer to look for potential intermediates. Supplementary Figure B.7
shows the Sankey diagram of literature overlap between the traits (Supplementary
Table 22), performed using the closed discovery approach (Figure 3b, 2.6.2) (view
interactively at https://mvab.shinyapps.io/literature_overlap_
sankey/).
The intermediate terms of this literature overlap include 120 unique (mostly

It is made available under a CC-BY 4.0 International license .

molecular) traits. Many of them are lipids-related traits (e.g., LDL, VLDL, ApoA,
ApoB, Lipase); others include interesting hypotheses such as testosterone, IGF-1,
insulin, CRP, and cathepsin D. Suitable GWAS datasets for MR validation were
found for 50 of the 120 traits (Supplementary Table 23).

We carried out MR bidirectionally between HDL-C ($ukb-d-30760_irnt$) and 448 42 potential intermediate traits (>=1 SNP) (Supplementary Tables 24 and 25), 449 followed by assessing their effect on breast cancer (Supplementary Table 26). A 450 subset of combined results from these three MR analyses is presented in Table 4.

From these results, the traits that fit the criteria for suggestive evidence of medi-451 ation are ApoA and testosterone. ApoA has been identified as a potential mediator 452 using MR-EvE as well. HDL-C has opposite effects on two types of testosterone: 453 negative on bioavailable and positive on total (Table 4), potentially indicating dif-454 ferent interaction mechanisms. Both testosterone measures have a risk-increasing 455 effect on breast cancer (previously reported in [61, 44]). In the literature overlap, 456 HDL is linked to testosterone via ApoE, HSD11B1, lipoproteins, and directly. In 457 turn, testosterone is linked to breast cancer directly or via estrogen/progestin (Fig-458 ure B.7). 459

Finally, cathepsin D (CTSD) has been identified as a potential intermediate in 460 the literature overlap (via CETP/endopeptidases and lipoprotein/cyclosporine, Fig-461 ure B.7). MR results show some evidence of HDL-C effect on CTSD (effect size 462 -0.12 [95% CI -0.23:-0.003], but little evidence of CTSD effect on breast cancer 463 (OR: 1.02 [95% CI 0.99:1.05], three *cis*-SNPs) (Table 4, Supplementary Table 26), 464 suggesting an unlikely role of CTSD as a mediator. However, the discovery of 465 a CTSD in literature overlap complements the finding of CTSDF in the MR-EvE 466 data (Table 3), indicating that the cathepsins may have a role in the relationship of 467 HDL-C and breast cancer, and the entire class of these enzymes should be explored 468 in future work. 469

470 4. Discussion

In this study, we used the EpiGraphDB knowledge graph to systematically identify breast cancer risk factors. Additionally, we integrated literature-mined and genetic data to determine potential mediators of the identified causal relationships between these risk factors and breast cancer, which we presented via two case studies.

Through mining MR-EvE data in EpiGraphDB we identified 2218 traits affecting breast cancer risk, which were narrowed down to 129 traits with reliable causal evidence following rigorous validation (Figure 4, https://mvab. shinyapps.io/MR_heatmaps/). The identified risk/protective factors included both molecular biomarkers and non-molecular traits. Many of these traits

It is made available under a CC-BY 4.0 International license .

Г	Et an 1 fammand	S4 1	<u>E4</u> 1
Mediator trait	(effect size,[95%CI])	(effect size, [95%CI])	Step 2 (OR, [95%CI])
Adiponectin ieu-a-1	0.1 [0.05:0.14]*		
Albumin met-c-841		0.05 [0:0.1]	
Apolipoprotein A-I met-c-842	0.71 [0.63:0.78]*	0.69 [0.60:0.77]*	0.64 [0.50:0.80]*
Apolipoprotein B ieu-b-108	-0.21 [-0.29:-0.12]*	-0.16 [-0.28:-0.05]*	
Basigin prot-a-275		0.11 [0.08:0.14]*	
CRP ukb-d-30710_irnt		0.03 [0.001:0.07]	
CAMK1 prot-a-347		-0.03 [-0.05:-0.01]*	
CAMK1 prot-a-346			0.98 [0.97:0.99]*
Cathepsin D prot-b-51	-0.12 [-0.23:-0.003]		
Ephrin-B2 prot-a-905		-0.04 [-0.07:-0.01]	
Histone deacetylase 8 prot-a-1320		-0.24 [-0.27:-0.21]*	
IGF-1 ukb-d-30770 irnt			1.07 [1.01:1.13]*
IGF1R prot-a-1444		-0.1 [-0.13:-0.08]*	0.82 [0.76:0.88]*
Lipoprotein A ukb-d-30790 irnt		0.01 [0.001:0.02]*	
Lipoprotein lipase ebi-a-GCST90010149	0.24 [0.04:0.45]	0.27 [0.24:0.29]*	
Oestradiol (F) ieu-b-4872		0.28 [0.17:0.39]*	
STARD1 prot-a-2866	-0.13 [-0.24:-0.01]		
Superoxide dismutase prot-a-2799	0.12 [0.01:0.24]	-0.01 [-0.02:-0.01]*	
Bio Testosterone (F) ieu-b-4869	-0.07 [-0.11:-0.03]*	-0.11 [-0.17:-0.05]*	1.12 [1.04:1.20]*
Total Testosterone (F) ieu-b-4864	0.03 [0.001:0.05]		1.14 [1.06:1.23]
Total esterified cholesterol met-d-Total_CE	0.33 [0.27:0.39]*	0.30 [0.10:0.50]*	
VLDL cholesterol met-d-VLDL_C	-0.31 [-0.37:-0.24]*	-0.36 [-0.56:-0.17]*	
L	1	1	1

Table 4: Subset of MR results (bidirectional and two-step) for potential mediators of HDL-C/breast cancer relationship, identified using LBD. The table combines the results from three MR analyses: *step 1 forward* (HDL-C \rightarrow mediator trait), *step 1 reverse* (mediator trait \rightarrow HDL-C), and *step 2* (mediator trait \rightarrow overall breast cancer). '*step 1 forward*' and '*step 1 reverse*' corresponded to bidirectional MR analysis; '*step 1 forward*' and '*step 2*' together correspond to two-step MR study design. The table only shows the results that pass the threshold of p.value < 0.05; the results that pass FDR are marked with an asterisk*. The full results are available in Supplementary Tables 24,25,26. *Abbreviations:* CRP - C-Reactive protein, CAMK1 - Calcium/calmodulin-dependent protein kinase type 1, STARD1- Steroidogenic acute regulatory protein; (F) - female-only data

It is made available under a CC-BY 4.0 International license .

have been reported before, e.g. anthropometric measures [48, 62, 63], reproduc-481 tive traits [44], sleep traits [51, 64], height [65], smoking behaviour [66, 67], 482 milk intake [68, 69], physical activity [70, 50, 71], lipids [52, 53, 54], metabo-483 lites [72], groups of proteins, e.g. adipokines [73], cytokines [74], inflammatory 484 markers [75], metalloproteinases [76] and other circulating proteins [77, 78]; ad-485 ditionally, several studies evaluated multiple risk factor groups [44, 79, 80, 71]. 486 Several molecular traits that have not previously been reported in MR studies in-487 clude betaine, SAT2, PRTN3, PLXNB2, DCBLD2, IDUA. Appendix C provides 488 an extended discussion of MR results of dietary and physical traits. 489

We presented two case study traits (*childhood body size* and *HDL-C*), for which 490 we identified potential mediators from MR-EvE data and literature data using our 491 LBD method, aiming to triangulate the evidence from both sources. Two-step 492 MR and sensitivity analyses were used to provide suggestive evidence of media-493 tion through the identified traits. In the *childhood body size* case study, MR-EvE 494 and literature-based mediator searches detected several overlapping traits, many of 495 which have been considered as potential mediators in an earlier hypothesis-driven 496 study [44] (e.g. IGF-1 and bioavailable testosterone), offering proof-of-concept 497 evidence for this approach, in addition to identifying several traits not considered 498 previously (e.g. physical activity and sleep duration). For HDL-C, the literature 499 overlap method identified several intermediates that also appeared in the MR-EvE 500 data (e.g. other lipid traits, ApoA, a cathepsin). HDL-C was also found to differen-501 tially affect total and bioavailable testosterone, which needs further investigation. 502 Additionally, the entire class of cathepsin enzymes needs to be assessed for their 503 mediating role in future work. 504

In our study, we took advantage of the pre-generated MR-EvE estimates in 505 EpiGraphDB through the R package (epigraphdb-r) [4], and demonstrated how it 506 enables fast hypothesis generation and prioritisation of candidate traits for more 507 targeted investigation. Originally, MR-EvE was developed to provide a causal map 508 of the human phenome, useful for supporting or rejecting specific hypotheses [14]. 509 However, for most traits, patterns of horizontal pleiotropy and issues with invalid 510 instruments were detected [14]. This highlighted the need for rigorous follow-511 up, including sensitivity analyses, biologically informed instrument selection, and 512 triangulation with other sources of evidence to validate the associations [14, 81]. 513 Hence, we validated our discoveries from MR-EvE using best practices in MR, 514 accompanied by sensitivity analyses, *cis*-instrument extraction for protein traits, 515 and also correction for multiple testing. 516

The MR-EvE data comes with several other limitations. Firstly, it is restricted to the traits available in OpenGWAS as of 2021, which were analysed in the everything-vs-everything way and subsequently added to EpiGraphDB. Secondly, a large proportion of those GWAS traits were measured in mixed-sex samples,

It is made available under a CC-BY 4.0 International license .

which suggests that traits with female-specific effects that are relevant for breast 521 cancer risk could have been overlooked in the analysis (e.g. IGF-1 [44], testos-522 terone [61]). Moreover, many known risk factors (from observational or previous 523 MR studies) may not come up in the MR-EvE review for several reasons, (1) some 524 traits are not heritable/instrumentable or not in OpenGWAS, (2) traits were mea-525 sured in another (larger) cohort, or with additional covariates (e.g. BMI), (3) the 526 filtering and FDR correction steps excluded traits with weaker evidence, which 527 may have been reported by smaller studies (e.g. LDL-C). 528

Many traits identified using MR-EvE in this work have been published as indi-529 vidual MR studies over the recent years, despite MR-EvE data being available via 530 EpiGraphDB since 2021 and earlier as a standalone resource (generated in 2017 by 531 Hemani et al [14]) [82]. This highlights MR-EvE's value in generating hypotheses 532 and guiding analyses, while also stressing the redundancy in the growing number 533 of MR studies, which often report only two-sample MR results without providing 534 further evidence, or attempting to dissect the underlying biological mechanisms 535 [83, 84]. 536

In our study, we address the need for evidence triangulation in MR studies by 537 incorporating literature-mined data to strengthen the evidence for identified rela-538 tionships and to generate hypotheses for underlying mechanisms. To achieve this, 539 we developed the LBD method (Figure 3) that helps to identify mechanistic path-540 ways or mediators for causal associations by mining literature data in EpiGraphDB. 541 The identified intermediate terms may then be tested using MR (given suitable 542 GWAS data is available). In both presented case studies, a third of the identi-543 fied intermediates provided testable hypotheses for MR validation. In this work, 544 we limited GWAS data search to OpenGWAS due to practical constraints, but fu-545 ture research could extend this search to other sources (e.g. GWAS catalog [85]) 546 and the newly released molecular datasets (e.g. proteomics data (Olink) [86] and 547 lipids/metabolites data (Nightingale NMR) [87]). 548

LBD and MR can mutually enhance each other: LBD can complement MR 549 causal inference by identifying potential intermediates, while MR validation of 550 LBD findings helps address challenges in evaluating discoveries and benchmark-551 ing the performance of LBD methods [88, 18]. Without proper evaluation, it's 552 difficult to determine the usefulness or practicality of a discovery, which hinders 553 the adoption of LBD in biomedical research [89]. Reviewing LBD discoveries with 554 MR (if the terms are instrumentable and data is available) offers a relatively quick 555 strategy for validation of the feasibility of the identified relationships. Certainly, 556 MR is not a definitive answer for assessing traits' causal associations or validating 557 a potential mediation mechanism. However, applying it to LBD discoveries may 558 help to prioritise the most plausible mechanisms, which could be taken further into 559 more costly and time-consuming validation. 560

It is made available under a CC-BY 4.0 International license .

Despite the potential gains of incorporating LBD into the biomedical/epidemi-561 ological research process, the limitations and pitfalls of working with literature-562 mined data should be noted. Even though literature space extraction from EpiGraphDB 563 is a straightforward process, the underlying raw triples data is noisy and may be 564 difficult to interpret. The extraction of semantic triples from text, mapping terms 565 to UMLS and later to GWAS phenotypes, is challenging and could be imprecise, 566 and therefore this data must be treated with caution. Additionally, it is impor-567 tant to note that the chains of intermediate terms (presented as Sankey diagrams) 568 should not be interpreted as true biological pathways. They simply represent re-569 lationships between biological entities mentioned in publications, and therefore 570 direct interactions cannot be assumed. Moreover, the extracted relationships may 571 also be affected by publication bias (i.e. due to abstracts often emphasising the 572 established knowledge). Therefore, any insights drawn from literature-mined data 573 must be traced back to the original publications to verify the validity of extracted 574 relationships before being used as evidence. 575

576 5. Conclusion

In this article, we presented a novel and efficient approach to undertake a sys-577 tematic investigation of breast cancer risk factors by mining EpiGraphDB, repre-578 senting the largest MR study of breast cancer so far. We also introduced a novel 579 LBD method for identifying potential intermediates or mechanisms between traits 580 of interest. Our data-driven approach highlighted that MR and LBD can be used 581 as complementary methods, providing supporting evidence to each other, as well 582 as guiding the generation of hypotheses and bringing evidence from observational 583 and genetic sources together. However, further validation through sensitivity tests, 584 MVMR, and mediation analyses (where appropriate) is essential, as these are im-585 portant steps in validation of causal relationships. The risk factors and mediators 586 identified in this work can be followed up in future studies in more detail, seeking 587 evidence from other analyses or sources, such as observational studies or lab-based 588 validation. Lastly, the overall approach can be used to study the aetiology of other 589 diseases. 590

591 6. CRediT authorship contribution statement

Marina Vabistsevits - Conceptualization, Formal analysis, Data curation, In vestigation, Methodology, Validation, Visualization, Writing – original draft, Writ ing – review and editing; Yi Liu - Supervision, Writing – review and editing,
 Methodology, Software; Tim Robinson - Supervision, Writing – review and edit ing; Ben Elsworth - Conceptualization, Supervision, Methodology, Software; Tom

It is made available under a CC-BY 4.0 International license .

R Gaunt - Conceptualization, Supervision, Methodology, Software, Writing – review and editing, Methodology, Project administration, Funding acquisition

599 7. Declaration of Competing Interest

T.R.G receives funding from Biogen and GSK for unrelated research.

601 8. Acknowledgments

M.V. is supported by the University of Bristol Alumni Fund (Professor Sir Eric 602 Thomas Scholarship). T.R. is supported by NIHR Development and Skills En-603 hancement Award (NIHR 302363) and has received grants to attend educational 604 workshops from Daiichi-Sankyo and Amgen. M.V., T.R., Y.L., T.R.G, work in the 605 Medical Research Council Integrative Epidemiology Unit at the University of Bris-606 tol supported by the Medical Research Council (MC_UU_00032/03). This work 607 was also supported by a Cancer Research UK programme grant (the Integrative 608 Cancer Epidemiology Programme) (CC18281/A29019). This study was also sup-609 ported by the NIHR Biomedical Research Centre at University Hospitals Bristol 610 NHS Foundation Trust and the University of Bristol. The views expressed in this 611 publication are those of the author(s) and not necessarily those of the NHS, the 612 National Institute for Health Research or the Department of Health. 613

It is made available under a CC-BY 4.0 International license .

614 Appendix A. Literature overlap method details

615 Appendix A.1. Literature-mined relationships in EpiGraphDB - extended version

EpiGraphDB contains literature-mined relationships between pairs of terms 616 (also known as 'literature triples') that were derived from the published literature. 617 Figure A.5 summarises the tools/databases involved in making literature-mined 618 data available in EpiGraphDB. Literature-mined relationships in EpiGraphDB were 619 originally extracted by the MELODI-Presto tool [38]. The underlying literature 620 data comes from SemMedDB (Semantic MEDLINE Database) [16], a well-established 621 repository of literature-mined semantic triples, i.e. 'subject term 1 - predicate -622 object term 2', mined from titles and abstracts of nearly 30 million biomedical arti-623 cles in PubMed, using SemRep [39, 40]. SemRep is a natural language processing 624 (NLP) system that parses biomedical text using linguistic principles and UMLS 625 (Unified Medical Language System) domain knowledge [90] to extract semantic 626 triples. 627



Figure A.5: A workflow diagram showing the origins of literature data in EpiGraphDB and the tools/databases involved in making this data available. EpiGraphDB literature term/triples nodes (on the right) is a subset of the full EpiGraphDB schema: https://www.epigraphdb.org/about

628 Appendix A.2. Literature space overlap method - extended version

Developing a method for connecting the literature spaces of exposure and out-629 come traits to explore potential links between them was one of the key aims of this 630 work. The underlying principle of the literature space overlap approach is linking 631 semantic triples of established biomedical knowledge into sequential 'chains', in 632 order to uncover new connections. This principle of triple linking has previously 633 been showcased in MELODI-Presto [38], and is an extension of the ABC paradigm 634 [41, 43] with the expansion of a chain of Bs $(B_1 \text{ to } B_i)$: AB_1^iC (see 2.6.2). The 635 details of the method are described below. 636

It is made available under a CC-BY 4.0 International license .

Triple cleaning. First, the extracted literature space for a trait is cleaned using 637 several strategies – terms are standardised to minimise redundancy (i.e. merging 638 long/short names, name acronyms, synonyms, gene/protein names); terms with 639 different entity types (e.g. *aapp* - amino acid/protein, *gngm* - gene/genome) are 640 filtered to include only the most common type; triples with the same term1 and 641 term2 are excluded; among bidirectionally related terms the ones with more more 642 common direction (indicated by triple score) is retained. Additionally, terms that 643 represented drugs/medications or other diseases (except anthropometrics-related 644 terms) as well as negative predicates (e.g. 'neg coexists with') are excluded. Fi-645 nally, a 'frequency score' is generated for each pair of terms, i.e. the sum of triple 646 scores across all possible predicates linking the terms, which is later used for triple 647 chaining visualisation (Sankey diagrams). 648

Term anchoring. To implement *closed discovery* from the ABC paradigm [43] 649 (see 2.6.2), we perform 'term anchoring', which involves restricting the outer term 650 in a chain of triples to be the trait itself. For example, for an exposure trait (e.g. 651 HDL-C), we are interested in downstream entities, so *term1* in the first triple of 652 a chain make from its literature space would be 'HDL' (Figure 3b: "T" for trait). 653 Inversely, in the breast cancer literature space, we are interested in entities upstream 654 of breast cancer, so we would restrict term2 of the terminal triple in the chain to be 655 'Breast cancer' (Figure 3b: "BC" for breast cancer). 656

For non-molecular traits, it is more difficult to perform term anchoring, because specific terms representing such traits are often not available. Therefore, for those we rely on *open discovery* [43] (see 2.6.2): the spaces are connected by matching unlinked triples from the exposure trait's literature space to any breast cancer triples, and then extending chaining of the matched triples upstream into the trait's space (Figure 3c).

Triple chaining. Literature spaces contain a variety of triples (some examples in 663 Table A.5), and only a small proportion of them contain the trait itself as a term. 664 Using only the triples that include the trait would make the analysis quite limited. 665 Therefore, 'triple chaining' is implemented as a part of the approach to extend 666 the discovery space. Within a trait's literature space, we generate a basic set of 667 triple chains, with the outer triple anchored to the trait term (see above), e.g. "T-668 A-B" and "C-D-E-F-BC", where letters A-E are terms forming chains (see Figure 669 3b). Then, the sets of triples from two literature spaces are "overlapped", which 670 involves *term2* from the exposure trait's space triples to match with *term1* in triples 671 from the breast cancer literature space. This can be done at any possible point, i.e. 672 not necessarily as the longest multiple-step chain (e.g. "T-A-B-C-D-E-F-BC"), but 673 can be of any variation (e.g. "T-A-B-BC", "T-D-E-F-BC"). 674

It is made available under a CC-BY 4.0 International license .

term1	predicate	term2	triple score	PubMed ID (year)
estradiol	interacts_with	Estrogen Receptors	59	26466867 (2016) / 17975893 (2007) []
PTEN	interacts_with	Proto-Oncogene c-akt	21	23650412 (2013) / 27044817 (2016) []
estrogens	stimulates	Tamoxifen	18	10070945 (1999) / 28052658 (2017) []
Cyclin D1	interacts_with	estrogens	8	29935900 (2017) / 17638066 (2008) []
PGR	coexists_with	Estrogen Receptor alpha	4	29403307 (2018) / 26153859 (2015) []
CHEK1	interacts_with	BRCA1	2	31789405 (2019) / 12094328 (2002)
O-GlcNAc transferase	interacts_with	Cytoplasmic Protein	2	21255644 (2011) / 23576270 (2013)
polyglutamine	coexists_with	BRCA1	2	23483928 (2013) / 20422428 (2011)
Tretinoin	stimulates	Protein Kinase C	2	15516986 (2004) / 9284950 (1997)
Steroid Hormones	inhibits	SHBG	2	1320387 (1992) / 2173856 (1990)
AP2A1	stimulates	TCEAL1	1	16288208 (2006)
Protein Kinase C	stimulates	CTGF	1	16813525 (2006)
FOXM1	interacts_with	BIRC4	1	26404623 (2015)

Table A.5: A subset of triples from the breast cancer literature space (*term1 - predicate - term2*) (randomly selected for illustrative purposes). The triple score indicates the number of publications the triple appears in/was extracted from. The 'PubMed ID (year)' column contains (a subset of) PubMed IDs of those publications. Full data is in Supplementary Table 14.

Literature spaces. The literature overlap method performs best on literature spaces 675 with > 50 triples, as this is required for effective triple chaining. Small literature 676 spaces are also less likely to contain the trait as a term, which is required for term 677 anchoring. Therefore, literature space sizes were also considered when choosing 678 case study traits, to ensure an effective application of the literature overlap method. 679 Literature spaces made of < 50 triples indicate that fewer publications were 680 found to be linked to them. This may be due to the trait being less studied (and 681 published about), or issues with the trait name (i.e. non-standard phasing of a 682 concept), or issues with the source data in SemMedDB [16] or trait mapping in 683 MELODI-Presto [38] (Figure A.5). Literature spaces of this size are generally 684 unusable in the literature space overlap method. 685

686 Appendix A.3. Literature spaces - extended details

Breast cancer. Breast cancer literature space was formed from data linked to two traits: 'Breast cancer' (OpenGWAS ID: *ieu-a-1126*) and 'Malignant neoplasm of the breast' (finn-a-C3_BREAST). 18,848 unique triples were identified, based on 4989 unique terms derived from 23,809 publications. The clean literature space is available in Supplementary Table 14. The breast cancer anchor term is 'Breast cancer', which is combined from the terms 'breast diseases' and 'malignant disease'.

Case studies. The selected case studies include *HDL* ('*HDL-cholesterol' - ukbd-30760_irnt*, 7808 unique triples) and *childhood body size* ('*childhood obesity'ieu-a-1096*, 1255 unique triples) (Supplementary Tables 15-16). For childhood body size, we chose to use '*childhood obesity*' literature space over '*Comparative body size at age 10*' (*ukb-b-4650*, 211 triples) due to the larger space size and trait name specificity.

It is made available under a CC-BY 4.0 International license .



700 Appendix B. Sankey diagrams for case studies

Figure B.6: Sankey diagram of childhood obesity and breast cancer literature spaces overlap, showing the overlap of literature triples within and between the spaces. The blue and orange relationships (triples) come from the childhood obesity and breast cancer literature spaces, respectively. The line width of each term relationship indicates how common it is in the literature (frequency score). Here, the open discovery approach was used, i.e. only one side of the overlap is anchored ('*Breast cancer*'); View interactively at https://mvab.shinyapps.io/ literature_overlap_sankey/

It is made available under a CC-BY 4.0 International license .



Figure B.7: Sankey diagram of HDL and breast cancer literature spaces overlap, showing how triples within and between HDL and breast cancer spaces interconnect. The blue and orange relationships (triples) come from the HDL and breast cancer literature spaces, respectively. The line width of each term relationship indicates how common it is in the literature (frequency score). Here, the closed discovery approach was used; the anchor terms are '*High Density Lipoproteins*' and '*Breast cancer*'. View interactively at https://mvab.shinyapps.io/literature_overlap_sankey/

701 Appendix C. Extended discussion of MR results for dietary and physical traits

The final set of 129 validated breast cancer risk factors identified from MR-702 EvE included several dietary traits. Genetically-proxied dietary intake exposures 703 require careful consideration due to the distinct sources of bias and interpretation 704 challenges they present. Dietary intake GWAS in UK Biobank can produce a con-705 siderable number of instruments due to their sample size, and the risk of horizontal 706 pleiotropy among these SNPs is high [91]. Trait heterogeneity is also important 707 to consider [92], i.e. the fact that genetic instruments associated with the dietary 708 trait may represent different 'dimensions' of the same trait, e.g. intake of a certain 709 food item and metabolism of its core component (e.g. coffee/caffeine [93]). The 710 primary risk in over-interpreting dietary intake MR lies in the possibility that the 711

It is made available under a CC-BY 4.0 International license .

extracted instruments may be non-informative or associated with dietary patterns through socio-demographic and behavioural factors, potentially confounding the MR results [91]. Additionally, dietary trait instruments often include adiposityrelated signals, meaning these variants could be affecting dietary patterns via their association with adiposity, leading to this association being captured in the MR results.

In this study, dietary traits with the most consistent evidence of effect were 718 'dried fruit intake' (showing a protective effect) and 'processed/sugary cereal in-719 take' (associated with an increased risk). Despite those MR results showing good 720 instrument strength and no strong indication for pleiotropy but some heterogene-721 ity, we cannot claim that the captured effect is specific to those food items. The 722 traits could be proxying two different environmental exposures, e.g. related to a 723 broader class of foods that share similar characteristics, or overall dietary pattern, 724 i.e. 'healthy' and 'unhealthy' food choices. The "gene-environment equivalence" 725 assumption in MR states that the downstream effect of exposure modification is 726 the same, regardless of it being genetically or non-genetically triggered. It could 727 be hypothesised that the personal preference/choice to consume dried fruit vs sug-728 ary/processed cereal could be reflective of the other dietary patterns in those in-729 dividuals' respective diets. Overall, the effect direction matches with the obser-730 vational evidence of diet impact on breast cancer risk [94]. The 'healthy' dietary 731 pattern includes a varied diet with high fruit and vegetable intake, which increases 732 the overall fibre and micronutrient content in the diet (more likely to occur in those 733 consuming dried fruit), while the 'unhealthy' pattern involves a larger amount of 734 processed and less nutrient-rich food items (more likely to occur in those choosing 735 to eat sweetened breakfast cereals). The genetic correlation analysis in the study 736 by Pirastu et al [95] has shown a positive correlation of 'dried fruit intake' GWAS 737 with other traits relating to a healthier diet (e.g. intake of fresh fruit, cooked veg, 738 fish, salad, being vegetarian) and a negative correlation with dietary patterns con-739 sidered less healthy (e.g. alcohol intake, processed meat, beef, spread on bread, 740 salt, instant coffee), supporting the idea that '*dried fruit intake*' instruments may 741 be proxying an overall healthier diet. The protective effect of 'dried fruit intake' on 742 breast cancer discovered from MR-EvE has been recently published in a separate 743 MR study [96], in which the authors also reviewed the most likely confounders 744 of this relationship (e.g. vitamin C, BMI, years of education) using MVMR, and 745 found that the identified inverse relationship is not affected when adjusted for any 746 of them. 747

Skimmed milk intake was another dietary trait identified from MR-EvE with evidence of a protective effect on breast cancer, but this result has to be carefully considered as it is misleading. Previous MR studies of milk intake effect [68, 69] selected instruments (nSNP=1) specifically within the lactase gene locus (*LCT*),

It is made available under a CC-BY 4.0 International license .

which encodes an enzyme that ensures tolerance of milk products. The variation 752 in this locus affects the amount of milk consumed and, therefore, is often used as a 753 proxy for this exposure. Both MR studies found a mild risk-increasing effect from 754 milk intake. In MR-EvE data, the instruments for 'skimmed milk intake' trait were 755 extracted genome-wide (nSNP=3), none of them being in LCT. MR sensitivity 756 tests identified likely horizontal pleiotropy and heterogeneity. This serves as a 757 valuable negative example of dietary traits evaluation and highlights the importance 758 of conducting more detailed investigations of these traits in individual studies. 759

Physical activity is one of the modifiable lifestyle factors that have been shown 760 to have a protective effect on breast cancer risk, particularly vigorous activity [97]. 761 MR studies using accelerometer-measured overall physical activity produced re-762 sults to support this [70, 50]. Among the physical activity traits available in MR-763 EvE (UK Biobank traits based on a survey question "Types of physical activity 764 in last 4 weeks"), several showed similar protective effects: 'Heavy DIY', 'stren-765 uous sports' and 'exercise to keep fit' (the last identified in a case study), which 766 may be proxying moderate-to-vigorous physical activity. Similarly, there was a 767 risk-increasing effect from 'no physical activity' trait, which is in agreement with 768 'sedentary time' found to increase the risk in [50] and the observationally-known 769 detrimental effects of physical inactivity [98]. With survey-derived physical activ-770 ity phenotypes (such as 'Heavy DIY') appearing unreliable, a potential follow-up 771 to these findings would be to compare the genetic instruments identified for physi-772 cal activity from survey phenotypes to those derived from accelerometer-measured 773 data. 774

775 **References**

 [1] D. A. Lawlor, K. Tilling, G. D. Smith, Triangulation in aetiological epidemiology, International Journal of Epidemiology 45 (6) (2017) 1866–1886.
 doi:10.1093/ije/dyw314.
 URL https://academic.oup.com/ije/article/45/6/1866/

- 780 2930550
- [2] M. R. Munafò, G. Davey Smith, Robust research needs many lines of
 evidence (1 2018). doi:10.1038/d41586-018-01023-3.

 783
 URL
 https://www.nature.com/articles/

 784
 d41586-018-01023-3

- [3] M. R. Munafò, J. P. Higgins, G. D. Smith, Triangulating evidence through the
 inclusion of genetically informed designs, Cold Spring Harbor Perspectives
 in Medicine 11 (8) (2021). doi:10.1101/cshperspect.a040659.
- 788 URL https://pubmed.ncbi.nlm.nih.gov/33355252/

It is made available under a CC-BY 4.0 International license .

[4] Y. Liu, B. Elsworth, P. Erola, V. Haberland, G. Hemani, M. Lyon, J. Zheng,

789

O. Lloyd, M. Vabistsevits, T. R. Gaunt, EpiGraphDB: A database and data 790 mining platform for health data science, Bioinformatics 37 (9) (2021) 1304-791 1311. doi:10.1093/bioinformatics/btaa961. 792 URL https://doi.org/10.1101/2020.08.01.230193 793 [5] D. Ochoa, A. Hercules, M. Carmona, D. Suveges, A. Gonzalez-Uriarte, 794 C. Malangone, A. Miranda, L. Fumis, D. Carvalho-Silva, M. Spitzer, 795 J. Baker, J. Ferrer, A. Raies, O. Razuvayevskaya, A. Faulconbridge, 796 E. Petsalaki, P. Mutowo, S. MacHlitt-Northen, G. Peat, E. McAuley, C. K. 797 Ong, E. Mountjoy, M. Ghoussaini, A. Pierleoni, E. Papa, M. Pignatelli, 798 G. Koscielny, M. Karim, J. Schwartzentruber, D. G. Hulcoop, I. Dunham, 799 E. M. McDonagh, Open Targets Platform: Supporting systematic drug-target 800 identification and prioritisation, Nucleic Acids Research 49 (D1) (2021) 801 D1302-D1310. doi:10.1093/nar/gkaa1027. 802 URL https://academic.oup.com/nar/article/49/D1/ 803 D1302/5983621 804 [6] A. Struck, B. Walsh, A. Buchanan, J. A. Lee, R. Spangler, J. M. Stu-805 art, K. Ellrott, Exploring Integrative Analysis Using the BioMedical 806 Evidence Graph, JCO Clinical Cancer Informatics 4 (2020) 147-159. 807 doi:10.1200/cci.19.00110. 808 https://ascopubs.org/doi/full/10.1200/CCI.19. URL 809 00110 810 [7] E. A. Coker, C. Mitsopoulos, J. E. Tym, A. Komianou, C. Kannas, 811 P. Di Micco, E. Villasclaras Fernandez, B. Ozer, A. A. Antolin, P. Work-812 man, B. Al-Lazikani, CanSAR: Update to the cancer translational research 813 and drug discovery knowledgebase, Nucleic Acids Research 47 (D1) (2019) 814 D917-D922. doi:10.1093/nar/gky1129. 815 URL https://pubmed.ncbi.nlm.nih.gov/33219674/ 816 [8] S. Ebrahim, G. Davey Smith, Mendelian randomization: Can genetic 817 epidemiology help redress the failures of observational epidemi-818 ology?, International Journal of Epidemiology 32 (1) (2003) 1-22. 819 doi:10.1007/s00439-007-0448-6. 820 URL https://link.springer.com/article/10.1007/ 821 s00439-007-0448-6 822 [9] E. Sanderson, M. M. Glymour, M. V. Holmes, H. Kang, J. Morrison, M. R. 823 Munafò, T. Palmer, C. M. Schooling, C. Wallace, Q. Zhao, G. Davey Smith, 824 Mendelian randomization, Nature Reviews Methods Primers 2 (1) (12 2022). 825

It is made available under a CC-BY 4.0 International license .

doi:10.1038/s43586-021-00092-5. 826 URL https://www.nature.com/articles/ 827 s43586-021-00092-5 828 [10] J. Xu, M. Li, Y. Gao, M. Liu, S. Shi, J. Shi, K. Yang, Z. Zhou, J. Tian, 829 Using Mendelian randomization as the cornerstone for causal inference in 830 epidemiology, Environmental Science and Pollution Research 29 (4) (2022) 831 5827-5839. doi:10.1007/s11356-021-15939-3. 832 URL https://pubmed.ncbi.nlm.nih.gov/34431050/ 833 [11] B. Elsworth, M. Lyon, T. Alexander, Y. Liu, P. Matthews, J. Hallett, P. Bates, 834 T. Palmer, V. Haberland, G. Davey Smith, J. Zheng, P. Haycock, T. R. Gaunt, 835 G. Hemani, B. Elsworth, M. Lyon, T. Alexander, Y. Liu, P. Matthews, J. Hal-836 lett, P. Bates, T. Palmer, V. Haberland, G. D. Smith, J. Zheng, P. Haycock, 837 T. R. Gaunt, G. Hemani, The MRC IEU OpenGWAS data infrastructure, 838 bioRxiv (8 2020). doi:10.1101/2020.08.10.244293. 839 URL https://doi.org/10.1101/2020.08.10.244293 840 [12] E. Sollis, A. Mosaku, A. Abid, A. Buniello, M. Cerezo, L. Gil, T. Groza, 841 O. Güneş, P. Hall, J. Hayhurst, A. Ibrahim, Y. Ji, S. John, E. Lewis, 842 J. A. Macarthur, A. Mcmahon, D. Osumi-Sutherland, K. Panoutsopoulou, 843 Z. Pendlington, S. Ramachandran, R. Stefancsik, J. Stewart, P. Whetzel, 844 R. Wilson, L. Hindorff, F. Cunningham, S. A. Lambert, M. Inouye, H. Parkin-845 son, L. W. Harris, The NHGRI-EBI GWAS Catalog: knowledgebase and 846 deposition resource, Nucleic Acids Research 51 (D1) (2023) D977-D985. 847 doi:10.1093/NAR/GKAC1010. 848 URL https://dx.doi.org/10.1093/nar/gkac1010 849 [13] G. Hemani, J. Zheng, B. Elsworth, K. H. Wade, V. Haberland, D. Baird, 850 C. Laurin, S. Burgess, J. Bowden, R. Langdon, V. Y. Tan, J. Yarmolin-851 sky, H. A. Shihab, N. J. Timpson, D. M. Evans, C. Relton, R. M. Martin, 852 G. Davey Smith, T. R. Gaunt, P. C. Haycock, The MR-base platform supports 853 systematic causal inference across the human phenome, eLife 7 (5 2018). 854 doi:10.7554/eLife.34408. 855 URL https://pubmed.ncbi.nlm.nih.gov/29846171/ 856 [14] G. Hemani, J. Bowden, P. Haycock, J. Zheng, O. Davis, P. Flach, T. Gaunt, 857 G. D. Smith, Automating Mendelian randomization through machine learn-858 ing to construct a putative causal map of the human phenome, bioRxiv (10) 859 (2017) 173682. doi:10.1101/173682. 860 URL https://www.biorxiv.org/content/10.1101/ 861 173682v2 862

It is made available under a CC-BY 4.0 International license .

```
[15] L. J. Jensen, J. Saric, P. Bork, Literature mining for the biologist: From infor-
863
        mation retrieval to biological discovery (2006). doi:10.1038/nrg1768.
864
        URL www.nature.com/reviews/genetics
865
   [16] H. Kilicoglu, D. Shin, M. Fiszman, G. Rosemblat, T. C. Rindflesch,
866
        SemMedDB: A PubMed-scale repository of biomedical semantic predi-
867
        cations, Bioinformatics 28 (23) (2012) 3158-3160.
                                                         doi:10.1093/
868
        bioinformatics/bts591.
869
        URL https://pubmed.ncbi.nlm.nih.gov/23044550/
870
    [17] T. Bekhuis, Conceptual biology, hypothesis discovery, and text min-
871
        ing: Swanson's legacy, Biomedical Digital Libraries 3 (1) (2006) 1-7.
872
        doi:10.1186/1742-5581-3-2/METRICS.
873
        URL https://bio-diglib.biomedcentral.com/articles/
874
        10.1186/1742-5581-3-2
875
   [18] G. Crichton, S. Baker, Y. Guo, A. Korhonen, Neural networks for open and
876
        closed Literature-based Discovery, PLoS ONE 15 (5) (2020) e0232891.
877
        doi:10.1371/journal.pone.0232891.
878
                https://journals.plos.org/plosone/article?id=
        URL
879
        10.1371/journal.pone.0232891
880
   [19] WCRF, World Cancer Research Fund/American Institute for Cancer Re-
881
        search. Continuous Update Project. Diet, Nutrition, Physical Activity and the
882
        Prevention of Cancer. Summary of evidence. (2018).
883
        URL www.wcrf.org/matrix
884
    [20] IARC, International Agency for Research on Cancer: Estimated cumulative
885
        risk of incidence in 2020, in females, in high-income countries, by cancer
886
        site; based on GLOBOSCAN 2020 data (2021).
887
        URL
                                        https://gco.iarc.fr/today/
888
        online-analysis-multi-bars?v=2020&mode=cancer&
889
        mode_population=countries&population=900&
890
        populations=986&key=cum_risk&sex=2&cancer=39&type=
891
        0&statistic=5&prevalence=0&population_group=0&ages_
892
        group%5B%5D=0&ages_group%5B%5D=14&nb_item
893
   [21] K. L. Britt, J. Cuzick, K. A. Phillips, Key steps for effective breast
894
        cancer prevention, Nature Reviews Cancer (2020).
                                                         doi:10.1038/
895
        s41568-020-0266-x.
896
        URL http://dx.doi.org/10.1038/s41568-020-0266-x
897
```

It is made available under a CC-BY 4.0 International license .

[22] N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poort-898 mans, K. Ruddy, J. Tsang, F. Cardoso, Breast cancer, Nature Reviews Disease 899 Primers 5 (1) (2019). doi:10.1038/s41572-019-0111-2. 900 URL https://pubmed.ncbi.nlm.nih.gov/31548545/ 901 [23] C. L. Relton, G. Davey Smith, Two-step epigenetic mendelian randomiza-902 tion: A strategy for establishing the causal role of epigenetic processes in 903 pathways to disease, International Journal of Epidemiology 41 (1) (2012) 904 161-176. doi:10.1093/ije/dyr233. 905 URL https://pubmed.ncbi.nlm.nih.gov/22422451/ 906 [24] J. Zheng, D. Baird, M.-C. Borges, J. Bowden, G. Hemani, P. Haycock, 907 D. M. Evans, G. D. Smith, Recent Developments in Mendelian Random-908 ization Studies, Current Epidemiology Reports 4 (4) (2017) 330-345. doi: 909 10.1007/s40471-017-0128-6. 910 URL https://doi.org/10.1007/s40471-017-0128-6 911 [25] K. Michailidou, S. Lindström, J. Dennis, J. Beesley, S. Hui, S. Kar, 912 A. Lemaçon, P. Soucy, D. Glubb, A. Rostamianfar, M. K. Bolla, Q. Wang, 913 J. Tyrer, E. Dicks, A. Lee, Z. Wang, J. Allen, R. Keeman, U. Eilber, J. D. 914 French, X. Qing Chen, L. Fachal, K. McCue, A. E. McCart Reed, M. Ghous-915 saini, J. S. Carroll, X. Jiang, H. Finucane, M. Adams, M. A. Adank, H. Ahsan, 916 K. Aittomäki, H. Anton-Culver, N. N. Antonenkova, V. Arndt, K. J. Aronson, 917 B. Arun, P. L. Auer, F. Bacot, M. Barrdahl, C. Baynes, M. W. Beckmann, 918 S. Behrens, J. Benitez, M. Bermisheva, L. Bernstein, C. Blomqvist, N. V. 919 Bogdanova, S. E. Bojesen, B. Bonanni, A.-L. Børresen-Dale, J. S. Brand, 920 H. Brauch, P. Brennan, H. Brenner, L. Brinton, P. Broberg, I. W. Brock, 921 A. Broeks, A. Brooks-Wilson, S. Y. Brucker, T. Brüning, B. Burwinkel, 922 K. Butterbach, Q. Cai, H. Cai, T. Caldés, F. Canzian, A. Carracedo, B. D. 923 Carter, J. E. Castelao, T. L. Chan, T.-Y. David Cheng, K. Seng Chia, J.-Y. 924 Choi, H. Christiansen, C. L. Clarke, M. Collée, D. M. Conroy, E. Cordina-925 Duverger, S. Cornelissen, D. G. Cox, A. Cox, S. S. Cross, J. M. Cunning-926 ham, K. Czene, M. B. Daly, P. Devilee, K. F. Doheny, T. Dörk, I. dos 927 Santos-Silva, M. Dumont, L. Durcan, M. Dwek, D. M. Eccles, A. B. Ekici, 928 A. Heather Eliassen, C. Ellberg, M. Elvira, C. Engel, M. Eriksson, P. A. 929 Fasching, J. Figueroa, D. Flesch-Janys, O. Fletcher, H. Flyger, L. Fritschi, 930 V. Gaborieau, M. Gabrielson, M. Gago-Dominguez, Y.-T. Gao, S. M. Gap-931 stur, J. A. García-Sáenz, M. M. Gaudet, V. Georgoulias, G. G. Giles, G. Glen-932 don, M. S. Goldberg, D. E. Goldgar, A. González-Neira, G. I. Grenaker Al-933 næs, M. Grip, J. Gronwald, A. Grundy, P. Guénel, L. Haeberle, E. Hah-934 nen, C. A. Haiman, N. Håkansson, U. Hamann, N. Hamel, S. Hankin-935

It is made available under a CC-BY 4.0 International license .

son, P. Harrington, S. N. Hart, J. M. Hartikainen, M. Hartman, A. Hein, 936 J. Heyworth, B. Hicks, P. Hillemanns, D. N. Ho, A. Hollestelle, M. J. 937 Hooning, R. N. Hoover, J. L. Hopper, M.-F. Hou, C.-N. Hsiung, G. Huang, 938 K. Humphreys, J. Ishiguro, H. Ito, M. Iwasaki, H. Iwata, A. Jakubowska, 939 W. Janni, E. M. John, N. Johnson, K. Jones, M. Jones, A. Jukkola-Vuorinen, 940 R. Kaaks, M. Kabisch, K. Kaczmarek, D. Kang, Y. Kasuga, M. J. Kerin, 941 S. Khan, E. Khusnutdinova, J. I. Kiiski, S.-W. Kim, J. A. Knight, V.-M. 942 Kosma, V. N. Kristensen, U. Krüger, A. Kwong, D. Lambrechts, L. Le Marc-943 hand, E. Lee, M. Hyuk Lee, J. Won Lee, C. Neng Lee, F. Lejbkowicz, 944 J. Li, J. Lilyquist, A. Lindblom, J. Lissowska, W.-Y. Lo, S. Loibl, J. Long, 945 A. Lophatananon, J. Lubinski, C. Luccarini, M. P. Lux, E. S. K Ma, R. J. 946 MacInnis, T. Maishman, E. Makalic, K. E. Malone, I. Maleva Kostovska, 947 A. Mannermaa, S. Manoukian, J. E. Manson, S. Margolin, S. Mariapun, 948 M. Elena Martinez, K. Matsuo, D. Mavroudis, J. McKay, C. McLean, 949 H. Meijers-Heijboer, A. Meindl, P. Menéndez, U. Menon, J. Meyer, H. Miao, 950 N. Miller, N. Aishah Mohd Taib, K. Muir, A. Marie Mulligan, C. Mulot, 951 S. L. Neuhausen, H. Nevanlinna, P. Neven, S. F. Nielsen, D.-Y. Noh, B. G. 952 Nordestgaard, A. Norman, O. I. Olopade, J. E. Olson, H. Olsson, C. Olswold, 953 N. Orr, V. Shane Pankratz, S. K. Park, T.-W. Park-Simon, R. Lloyd, J. I. 954 A Perez, P. Peterlongo, J. Peto, K.-A. Phillips, M. Pinchev, D. Plaseska-955 Karanfilska, R. Prentice, N. Presneau, D. Prokofyeva, E. Pugh, K. Pylkäs, 956 B. Rack, P. Radice, N. Rahman, G. Rennert, H. S. Rennert, V. Rhenius, 957 A. Romero, J. Romm, K. J. Ruddy, T. Rüdiger, A. Rudolph, M. Ruebner, 958 E. J. T Rutgers, E. Saloustros, D. P. Sandler, S. Sangrajrang, E. J. Sawyer, 959 D. F. Schmidt, R. K. Schmutzler, A. Schneeweiss, M. J. Schoemaker, F. Schu-960 macher, P. Schürmann, R. J. Scott, C. Scott, S. Seal, C. Seynaeve, M. Shah, 961 P. Sharma, C.-Y. Shen, G. Sheng, M. E. Sherman, M. J. Shrubsole, X.-O. Shu, 962 A. Smeets, C. Sohn, M. C. Southey, J. J. Spinelli, C. Stegmaier, S. Stewart-963 Brown, J. Stone, D. O. Stram, H. Surowy, A. Swerdlow, R. Tamimi, J. A. 964 Taylor, M. Tengström, S. H. Teo, M. Beth Terry, D. C. Tessier, S. Thana-965 sitthichai, K. Thöne, R. A. E M Tollenaar, I. Tomlinson, L. Tong, D. Tor-966 res, T. Truong, C.-C. Tseng, S. Tsugane, H.-U. Ulmer, G. Ursin, M. Untch, 967 C. Vachon, C. J. van Asperen, D. Van Den Berg, A. M. W van den Ouweland, 968 L. van der Kolk, R. B. van der Luijt, D. Vincent, J. Vollenweider, Q. Waisfisz, 969 S. Wang-Gohrke, C. R. Weinberg, C. Wendt, A. S. Whittemore, H. Wildiers, 970 W. Willett, R. Winqvist, A. Wolk, A. H. Wu, L. Xia, T. Yamaji, X. R. Yang, 971 C. Har Yip, K.-Y. Yoo, J.-C. Yu, W. Zheng, Y. Zheng, B. Zhu, A. Ziogas, 972 E. Ziv, S. R. Lakhani, A. C. Antoniou, A. Droit, I. L. Andrulis, C. I. Amos, 973 F. J. Couch, P. D. P Pharoah, J. Chang-Claude, P. Hall, D. J. Hunter, R. L. 974 Milne, M. García-Closas, M. K. Schmidt, S. J. Chanock, A. M. Dunning, 975

It is made available under a CC-BY 4.0 International license .

- S. L. Edwards, G. D. Bader, G. Chenevix-Trench, J. Simard, P. Kraft, D. F.
- Easton, Association analysis identifies 65 new breast cancer risk loci, Nature
- 978 (2017). doi:10.1038/nature24284.
- 979 URL www.nature.com/reprints.

[26] H. Zhang, T. U. Ahearn, J. Lecarpentier, D. Barnes, J. Beesley, G. Qi, 980 X. Jiang, T. A. O'Mara, N. Zhao, M. K. Bolla, A. M. Dunning, J. Dennis, 981 Q. Wang, Z. A. Ful, K. Aittomäki, I. L. Andrulis, H. Anton-Culver, V. Arndt, 982 K. J. Aronson, B. K. Arun, P. L. Auer, J. Azzollini, D. Barrowdale, H. Becher, 983 M. W. Beckmann, S. Behrens, J. Benitez, M. Bermisheva, K. Bialkowska, 984 A. Blanco, C. Blomqvist, N. V. Bogdanova, S. E. Bojesen, B. Bonanni, 985 D. Bondavalli, A. Borg, H. Brauch, H. Brenner, I. Briceno, A. Broeks, 986 S. Y. Brucker, T. Brüning, B. Burwinkel, S. S. Buys, H. Byers, T. Caldés, 987 M. A. Caligo, M. Calvello, D. Campa, J. E. Castelao, J. Chang-Claude, S. J. 988 Chanock, M. Christiaens, H. Christiansen, W. K. Chung, K. B. Claes, C. L. 989 Clarke, S. Cornelissen, F. J. Couch, A. Cox, S. S. Cross, K. Czene, M. B. 990 Daly, P. Devilee, O. Diez, S. M. Domchek, T. Dörk, M. Dwek, D. M. Eccles, 991 A. B. Ekici, D. G. Evans, P. A. Fasching, J. Figueroa, L. Foretova, F. Fo-992 stira, E. Friedman, D. Frost, M. Gago-Dominguez, S. M. Gapstur, J. Gar-993 ber, J. A. García-Sáenz, M. M. Gaudet, S. A. Gayther, G. G. Giles, A. K. 994 Godwin, M. S. Goldberg, D. E. Goldgar, A. González-Neira, M. H. Greene, 995 J. Gronwald, P. Guénel, L. Häberle, E. Hahnen, C. A. Haiman, C. R. Hake, 996 P. Hall, U. Hamann, E. F. Harkness, B. A. Heemskerk-Gerritsen, P. Hille-997 manns, F. B. Hogervorst, B. Holleczek, A. Hollestelle, M. J. Hooning, R. N. 998 Hoover, J. L. Hopper, A. Howell, H. Huebner, P. J. Hulick, E. N. Imyani-999 tov, C. Isaacs, L. Izatt, A. Jager, M. Jakimovska, A. Jakubowska, P. James, 1000 R. Janavicius, W. Janni, E. M. John, M. E. Jones, A. Jung, R. Kaaks, P. M. 1001 Kapoor, B. Y. Karlan, R. Keeman, S. Khan, E. Khusnutdinova, C. M. Kita-1002 hara, Y. D. Ko, I. Konstantopoulou, L. B. Koppert, S. Koutros, V. N. Kris-1003 tensen, A. V. Laenkholm, D. Lambrechts, S. C. Larsson, P. Laurent-Puig, 1004 C. Lazaro, E. Lazarova, F. Lejbkowicz, G. Leslie, F. Lesueur, A. Lind-1005 blom, J. Lissowska, W. Y. Lo, J. T. Loud, J. Lubinski, A. Lukomska, R. J. 1006 MacInnis, A. Mannermaa, M. Manoochehri, S. Manoukian, S. Margolin, 1007 M. E. Martinez, L. Matricardi, L. McGuffog, C. McLean, N. Mebirouk, 1008 A. Meindl, U. Menon, A. Miller, E. Mingazheva, M. Montagna, A. M. Mulli-1009 gan, C. Mulot, T. A. Muranen, K. L. Nathanson, S. L. Neuhausen, H. Nevan-1010 linna, P. Neven, W. G. Newman, F. C. Nielsen, L. Nikitina-Zake, J. Nodora, 1011 K. Offit, E. Olah, O. I. Olopade, H. Olsson, N. Orr, L. Papi, J. Papp, T. W. 1012 Park-Simon, M. T. Parsons, B. Peissel, A. Peixoto, B. Peshkin, P. Peterlongo, 1013 J. Peto, K. A. Phillips, M. Piedmonte, D. Plaseska-Karanfilska, K. Prajzen-1014

It is made available under a CC-BY 4.0 International license .

danc, R. Prentice, D. Prokofyeva, B. Rack, P. Radice, S. J. Ramus, J. Rantala, 1015 M. U. Rashid, G. Rennert, H. S. Rennert, H. A. Risch, A. Romero, M. A. 1016 Rookus, M. Rübner, T. Rüdiger, E. Saloustros, S. Sampson, D. P. Sandler, 1017 E. J. Sawyer, M. T. Scheuner, R. K. Schmutzler, A. Schneeweiss, M. J. Schoe-1018 maker, B. Schöttker, P. Schürmann, L. Senter, P. Sharma, M. E. Sherman, 1019 X. O. Shu, C. F. Singer, S. Smichkoska, P. Soucy, M. C. Southey, J. J. Spinelli, 1020 J. Stone, D. Stoppa-Lyonnet, A. J. Swerdlow, C. I. Szabo, R. M. Tamimi, 1021 W. J. Tapper, J. A. Taylor, M. R. Teixeira, M. B. Terry, M. Thomassen, D. L. 1022 Thull, M. Tischkowitz, A. E. Toland, R. A. Tollenaar, I. Tomlinson, D. Torres, 1023 M. A. Troester, T. Truong, N. Tung, M. Untch, C. M. Vachon, A. M. van den 1024 Ouweland, L. E. van der Kolk, E. M. van Veen, E. J. vanRensburg, A. Vega, 1025 B. Wappenschmidt, C. R. Weinberg, J. N. Weitzel, H. Wildiers, R. Winqvist, 1026 A. Wolk, X. R. Yang, D. Yannoukakos, W. Zheng, K. K. Zorn, R. L. Milne, 1027 P. Kraft, J. Simard, P. D. Pharoah, K. Michailidou, A. C. Antoniou, M. K. 1028 Schmidt, G. Chenevix-Trench, D. F. Easton, N. Chatterjee, M. García-Closas, 1029 Genome-wide association study identifies 32 novel breast cancer susceptibil-1030 ity loci from overall and subtype-specific analyses, Nature Genetics 52 (6) 1031 (2020) 572-581. doi:10.1038/s41588-020-0609-2. 1032 URL https://pubmed.ncbi.nlm.nih.gov/32424353/ 1033 [27] L. Darrous, N. Mounier, Z. Kutalik, Simultaneous estimation of bi-1034 directional causal effects and heritable confounding from GWAS sum-1035 mary statistics, Nature Communications 2021 12:1 12 (1) (2021) 1-15. 1036 doi:10.1038/s41467-021-26970-w. 1037 URL https://www.nature.com/articles/ 1038 s41467-021-26970-w 1039 [28] S. Burgess, G. D. Smith, N. M. Davies, F. Dudbridge, D. Gill, M. M. Gly-1040

[28] S. Burgess, G. D. Smith, N. M. Davies, F. Dudbridge, D. Gill, M. M. Glymour, F. P. Hartwig, M. V. Holmes, C. Minelli, C. L. Relton, E. Theodoratou,
G. Davey Smith, N. M. Davies, F. Dudbridge, D. Gill, M. M. Glymour, F. P.
Hartwig, M. V. Holmes, C. Minelli, C. L. Relton, E. Theodoratou, Guidelines
for performing Mendelian randomization investigations, Wellcome Open Research 4 (2023) 186. doi:10.12688/wellcomeopenres.15555.2.
URL https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC7384151/

[29] V. W. Skrivankova, R. C. Richmond, B. A. Woolf, N. M. Davies, S. A. Swanson, T. J. Vanderweele, N. J. Timpson, J. P. Higgins, N. Dimou, C. Langenberg, E. W. Loder, R. M. Golub, M. Egger, G. D. Smith, J. B. Richards,
Strengthening the reporting of observational studies in epidemiology using
mendelian randomisation (STROBE-MR): explanation and elaboration, BMJ

It is made available under a CC-BY 4.0 International license .

1053 1054		375(102021).doi:10.1136/BMJ.N2233. URL https://www.bmj.com/content/375/bmj.n2233
1055 1056 1057 1058 1059 1060 1061 1062 1063	[30]	V. W. Skrivankova, R. C. Richmond, B. A. Woolf, J. Yarmolinsky, N. M. Davies, S. A. Swanson, T. J. Vanderweele, J. P. Higgins, N. J. Timpson, N. Dimou, C. Langenberg, R. M. Golub, E. W. Loder, V. Gallo, A. Tybjaerg-Hansen, G. Davey Smith, M. Egger, J. B. Richards, Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement, JAMA 326 (16) (2021) 1614–1621. doi:10.1001/JAMA.2021.18236. URL https://jamanetwork.com/journals/jama/fullarticle/2785494
1064 1065 1066 1067 1068 1069	[31]	 A. F. Schmidt, C. Finan, M. Gordillo-Marañón, F. W. Asselbergs, D. F. Freitag, R. S. Patel, B. Tyl, S. Chopade, R. Faraway, M. Zwierzyna, A. D. Hingorani, Genetic drug target validation using Mendelian randomisation, Nature Communications 11 (1) (2020). doi:10.1038/s41467-020-16969-0. URL http://dx.doi.org/10.1038/s41467-020-16969-0
1070 1071 1072 1073	[32]	S. Burgess, A. Butterworth, S. G. Thompson, Mendelian randomization anal- ysis with multiple genetic variants using summarized data, Genetic Epidemi- ology 37 (7) (2013) 658–665. doi:10.1002/gepi.21758. URL https://pubmed.ncbi.nlm.nih.gov/24114802/
1074 1075 1076 1077 1078 1079	[33]	J. Bowden, G. Davey Smith, S. Burgess, Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression, International Journal of Epidemiology 44 (2) (2015) 512-525. doi:10.1093/ije/dyv080. URL https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4849733/
1080 1081 1082 1083 1084 1085	[34]	J. Bowden, G. Davey Smith, P. C. Haycock, S. Burgess, Consistent Estima- tion in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator, Genetic Epidemiology 40 (4) (2016) 304–314. doi:10.1002/gepi.21965. URL https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4849733/
1086 1087 1088	[35]	J. Bowden, F. Del Greco M, C. Minelli, Q. Zhao, D. A. Lawlor, N. A. Sheehan, J. Thompson, G. Davey Smith, Improving the accuracy of two- sample summary-data Mendelian randomization: Moving beyond the NOME

It is made available under a CC-BY 4.0 International license .

```
assumption, International Journal of Epidemiology 48 (3) (2019) 728-742.
1089
         doi:10.1093/ije/dyy258.
1090
         URL https://academic.oup.com/ije/article-abstract/
1091
         48/3/728/5251908
1092
    [36] E. Sanderson, W. Spiller, J. Bowden, Testing and correcting for weak and
1093
         pleiotropic instruments in two-sample multivariable Mendelian randomiza-
1094
         tion, Stat Med. 40 (25) (2021) 5434-5452.
1095
         URL https://pubmed.ncbi.nlm.nih.gov/34338327/
1096
    [37] D. G. Altman, P. Royston, The cost of dichotomising continuous variables,
1097
         British Medical Journal 332 (7549) (2006) 1080. doi:10.1136/bmj.
1098
         332.7549.1080.
1099
    [38] B. Elsworth, T. R. Gaunt, MELODI Presto: A fast and agile tool to explore
1100
         semantic triples derived from biomedical literature, Bioinformatics 37 (4)
1101
         (2021) 583-585. doi:10.1093/bioinformatics/btaa726.
1102
                       https://academic.oup.com/bioinformatics/
         URL
1103
         advance-article/doi/10.1093/bioinformatics/btaa726/
1104
         5893950
1105
    [39] T. C. Rindflesch, M. Fiszman, The interaction of domain knowledge and
1106
         linguistic structure in natural language processing: interpreting hypernymic
1107
         propositions in biomedical text, Journal of Biomedical Informatics 36 (6)
1108
         (2003) 462-477. doi:10.1016/J.JBI.2003.11.003.
1109
         URL https://pubmed.ncbi.nlm.nih.gov/14759819/
1110
    [40] H. Kilicoglu, G. Rosemblat, M. Fiszman, D. Shin, Broad-coverage biomed-
1111
         ical relation extraction with SemRep, BMC Bioinformatics 21 (1) (2020)
1112
         1-28. doi:10.1186/S12859-020-3517-7/TABLES/4.
1113
                  https://bmcbioinformatics.biomedcentral.com/
         URL
1114
         articles/10.1186/s12859-020-3517-7
1115
    [41] N. R. Smalheiser, Rediscovering Don Swanson: The Past, Present and Future
1116
         of Literature-based Discovery, Journal of Data and Information Science 2 (4)
1117
         (2017) 43-64. doi:10.1515/JDIS-2017-0019.
1118
         URL
                     https://www.ncbi.nlm.nih.gov/pmc/articles/
1119
         PMC5771422/
1120
    [42] D. R. Swanson, Fish oil, Raynaud's syndrome, and undiscovered public
1121
         knowledge., Perspectives in biology and medicine 30 (1) (1986) 7-18. doi:
1122
         10.1353/pbm.1986.0087.
1123
         URL https://pubmed.ncbi.nlm.nih.gov/3797213/
1124
```

It is made available under a CC-BY 4.0 International license .

[43] M. Weeber, H. Klein, L. T. De Jong-Van Den Berg, R. Vos, Using concepts in literature-based discovery: Simulating Swanson's Raynaud-fish oil and migraine-magnesium discoveries, Journal of the American Society for Information Science and Technology 52 (7) (2001) 548–557.
doi:10.1002/asi.1104.

1130 URL https://onlinelibrary.wiley.com/doi/10.1002/ 1131 asi.1104

[44] M. Vabistsevits, G. Davey Smith, E. Sanderson, T. G. Richardson, B. LloydLewis, R. C. Richmond, Deciphering how early life adiposity influences
breast cancer risk using Mendelian randomization, Communications Biology
5 (1) (2022). doi:10.1038/s42003-022-03272-5.

[45] B. Jassal, L. Matthews, G. Viteri, C. Gong, P. Lorente, A. Fabregat,
K. Sidiropoulos, J. Cook, M. Gillespie, R. Haw, F. Loney, B. May, M. Milacic, K. Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, J. Weiser,
G. Wu, L. Stein, H. Hermjakob, P. D'Eustachio, The reactome pathway
knowledgebase, Nucleic Acids Research 48 (D1) (2020) D498–D503. doi:
10.1093/nar/gkz1031.

1142 URL https://pubmed.ncbi.nlm.nih.gov/31691815/

[46] H. J. Baer, S. S. Tworoger, S. E. Hankinson, W. C. Willett, Body fatness at
young ages and risk of breast cancer throughout life, American Journal of
Epidemiology 171 (11) (2010) 1183–1194. doi:10.1093/aje/kwq045.
URL https://academic.oup.com/aje/article-abstract/
171/11/1183/101419

[47] A. Furer, A. Afek, A. Sommer, L. Keinan-Boker, E. Derazne, Z. Levi,
D. Tzur, S. Tiosano, A. Shina, Y. Glick, J. D. Kark, A. Tirosh, G. Twig,
Adolescent obesity and midlife cancer risk: a population-based cohort study
of 2.3 million adolescents in Israel, The Lancet Diabetes and Endocrinology
8 (2) (2020) 216 (225 - 10.1016) (20012) 0507 (00) 20010 - W

1152 8 (3) (2020) 216-225. doi:10.1016/S2213-8587 (20) 30019-X.

URL http://dx.doi.org/10.1016/S2213-8587(20)30019-X

[48] T. G. Richardson, E. Sanderson, B. Elsworth, K. Tilling, G. Davey Smith,
Use of genetic variation to separate the effects of early and later life adiposity
on disease risk: Mendelian randomisation study, The BMJ 369 (2020). doi:
10.1136/bmj.m1203.

1158 URL http://dx.doi.org/10.1136/bmj.m1203

[49] Y. Hao, J. Xiao, Y. Liang, X. Wu, H. Zhang, C. Xiao, L. Zhang, S. Burgess,
N. Wang, X. Zhao, P. Kraft, J. Li, X. Jiang, Reassessing the causal role

It is made available under a CC-BY 4.0 International license .

of obesity in breast cancer susceptibility: A comprehensive multivariable
 Mendelian randomization investigating the distribution and timing of
 exposure, International Journal of Epidemiology 52 (1) (2023) 58–70.
 doi:10.1093/ije/dyac143.

1165 URL https://www.ncbi.nlm.nih.gov/pmc/articles/ 1166 PMC7614158/

[50] S. C. Dixon-Suen, S. J. Lewis, R. M. Martin, D. R. English, T. Boyle, 1167 G. G. Giles, K. Michailidou, M. K. Bolla, Q. Wang, J. Dennis, M. Lush, 1168 A. Investigators, T. U. Ahearn, C. B. Ambrosone, I. L. Andrulis, H. Anton-1169 Culver, V. Arndt, K. J. Aronson, A. Augustinsson, P. Auvinen, L. E. Freeman, 1170 H. Becher, M. W. Beckmann, S. Behrens, M. Bermisheva, C. Blomqvist, 1171 N. V. Bogdanova, S. E. Bojesen, B. Bonanni, H. Brenner, T. Brüning, 1172 S. S. Buys, N. J. Camp, D. Campa, F. Canzian, J. E. Castelao, M. H. 1173 Cessna, J. Chang-Claude, S. J. Chanock, C. L. Clarke, D. M. Conroy, F. J. 1174 Couch, A. Cox, S. S. Cross, K. Czene, M. B. Daly, P. Devilee, T. Dörk, 1175 M. Dwek, D. M. Eccles, A. H. Eliassen, C. Engel, M. Eriksson, D. G. 1176 Evans, P. A. Fasching, O. Fletcher, H. Flyger, L. Fritschi, M. Gabriel-1177 son, M. Gago-Dominguez, M. García-Closas, J. A. García-Sáenz, M. S. 1178 Goldberg, P. Guénel, M. Gündert, E. Hahnen, C. A. Haiman, L. Häberle, 1179 N. Håkansson, P. Hall, U. Hamann, S. N. Hart, M. Harvie, P. Hillemanns, 1180 A. Hollestelle, M. J. Hooning, R. Hoppe, J. Hopper, A. Howell, D. J. Hunter, 1181 A. Jakubowska, W. Janni, E. M. John, A. Jung, R. Kaaks, R. Keeman, C. M. 1182 Kitahara, S. Koutros, P. Kraft, V. N. Kristensen, K. Kubelka-Sabit, A. W. 1183 Kurian, J. V. Lacey, D. Lambrechts, L. Le Marchand, A. Lindblom, S. Loibl, 1184 J. Lubiński, A. Mannermaa, M. Manoochehri, S. Margolin, M. E. Martinez, 1185 D. Mavroudis, U. Menon, A. M. Mulligan, R. A. Murphy, N. Collabora-1186 tors, H. Nevanlinna, I. Nevelsteen, W. G. Newman, K. Offit, A. F. Olshan, 1187 H. Olsson, N. Orr, A. Patel, J. Peto, D. Plaseska-Karanfilska, N. Presneau, 1188 B. Rack, P. Radice, E. Rees-Punia, G. Rennert, H. S. Rennert, A. Romero, 1189 E. Saloustros, D. P. Sandler, M. K. Schmidt, R. K. Schmutzler, L. Schwent-1190 ner, C. Scott, M. Shah, X. O. Shu, J. Simard, M. C. Southey, J. Stone, 1191 H. Surowy, A. J. Swerdlow, R. M. Tamimi, W. J. Tapper, J. A. Taylor, M. B. 1192 Terry, R. A. Tollenaar, M. A. Troester, T. Truong, M. Untch, C. M. Vachon, 1193 V. Joseph, B. Wappenschmidt, C. R. Weinberg, A. Wolk, D. Yannoukakos, 1194 W. Zheng, A. Ziogas, A. M. Dunning, P. D. Pharoah, D. F. Easton, R. L. 1195 Milne, B. M. Lynch, Physical activity, sedentary time and breast cancer risk: 1196 a Mendelian randomisation study, British Journal of Sports Medicine 56 (20) 1197 (2022) 1157-1170. doi:10.1136/bjsports-2021-105132. 1198 URL https://bjsm.bmj.com/content/56/20/1157 1199

It is made available under a CC-BY 4.0 International license .

1200 1201 1202 1203 1204 1205 1206	[51]	R. C. Richmond, E. L. Anderson, H. S. Dashti, S. E. Jones, J. M. Lane, L. B. Strand, B. Brumpton, M. K. Rutter, A. R. Wood, K. Straif, C. L. Relton, M. Munafò, T. M. Frayling, R. M. Martin, R. Saxena, M. N. Weedon, D. A. Lawlor, G. D. Smith, Investigating causal relations between sleep traits and risk of breast cancer in women: Mendelian randomisation study, The BMJ 365 (2019). doi:10.1136/bmj.12327. URL http://dx.doi.org/10.1136/bmj.12327
1207 1208 1209 1210	[52]	C. Nowak, J. Ärnlöv, A Mendelian randomization study of the effects of blood lipids on breast cancer risk, Nature communications 9 (1) (12 2018). doi:10.1038/S41467-018-06467-9. URL https://pubmed.ncbi.nlm.nih.gov/30262900/
1211 1212 1213 1214 1215 1216 1217 1218	[53]	A. Beeghly-Fadiel, N. K. Khankari, R. J. Delahanty, X. O. Shu, Y. Lu, M. K. Schmidt, M. K. Bolla, K. Michailidou, Q. Wang, J. Dennis, D. Yan- noukakos, A. M. Dunning, P. D. Pharoah, G. Chenevix-Trench, R. L. Milne, D. J. Hunter, H. Per, P. Kraft, J. Simard, D. F. Easton, W. Zheng, A Mendelian randomization analysis of circulating lipid traits and breast can- cer risk, International Journal of Epidemiology 49 (4) (2020) 1117–1131. doi:10.1093/ije/dyz242. URL https://pubmed.ncbi.nlm.nih.gov/31872213/
1219 1220 1221 1222 1223 1224	[54]	K. E. Johnson, K. M. Siewert, D. Klarin, S. M. Damrauer, K. M. Chang, P. S. Tsao, T. L. Assimes, K. N. Maxwell, B. F. Voight, The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study, PLoS Medicine 17 (9) (2020) 1–21. doi:10.1371/JOURNAL.PMED. 1003302. URL https://pubmed.ncbi.nlm.nih.gov/32915777/
1225 1226 1227 1228 1229 1230	[55]	M. Touvier, P. Fassier, M. His, T. Norat, D. S. Chan, J. Blacher, S. Her- cberg, P. Galan, N. Druesne-Pecollo, P. Latino-Martel, Cholesterol and breast cancer risk: A systematic review and meta-analysis of prospective stud- ies, British Journal of Nutrition 114 (3) (2015) 347–357. doi:10.1017/ S000711451500183X. URL https://pubmed.ncbi.nlm.nih.gov/26173770/
1231 1232 1233 1234 1235	[56]	L. Lindstedt, M. Lee, K. Öörni, D. Brömme, P. T. Kovanen, Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells, Bio- chemical and Biophysical Research Communications 312 (4) (2003) 1019– 1024. doi:10.1016/j.bbrc.2003.11.020. URL https://pubmed.ncbi.nlm.nih.gov/14651973/

It is made available under a CC-BY 4.0 International license .

1236 1237 1238 1239 1240 1241	[57]	N. Spielmann, D. M. Mutch, F. Rousseau, F. Tores, J. Hager, S. Bertrais, A. Basdevant, P. Tounian, B. Dubern, P. Galan, K. Clément, Cathepsin S genotypes are associated with Apo-A1 and HDL-cholesterol in lean and obese French populations, Clinical Genetics 74 (2) (2008) 155–163. doi: 10.1111/j.1399-0004.2008.01043.x. URL https://pubmed.ncbi.nlm.nih.gov/18565099/
1242 1243 1244 1245 1246	[58]	L. Ren, J. Yi, W. Li, X. Zheng, J. Liu, J. Wang, G. Du, Apolipopro- teins and cancer, Cancer Medicine 8 (16) (2019) 7032-7043. doi:10.1002/cam4.2587. URL https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC6853823/
1247 1248 1249 1250	[59]	O. C. Olson, J. A. Joyce, Cysteine cathepsin proteases: Regulators of cancer progression and therapeutic response, Nature Reviews Cancer 15 (12) (2015) 712-729. doi:10.1038/nrc4027. URL https://pubmed.ncbi.nlm.nih.gov/26597527/
1251 1252 1253 1254 1255 1256	[60]	M. Rudzińska, A. Parodi, S. M. Soond, A. Z. Vinarov, D. O. Korolev, A. O. Morozov, C. Daglioglu, Y. Tutar, A. A. Zamyatnin, The Role of Cysteine Cathepsins in Cancer Progression and Drug Resistance, International Journal of Molecular Sciences 20 (14) (7 2019). doi:10.3390/IJMS20143602. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678516/
1257 1258 1259 1260 1261 1262 1263 1264 1265	[61]	K. S. Ruth, F. R. Day, J. Tyrrell, D. J. Thompson, A. R. Wood, A. Mahajan, R. N. Beaumont, L. Wittemans, S. Martin, A. S. Busch, A. M. Erzurum- luoglu, B. Hollis, T. A. O'Mara, M. I. McCarthy, C. Langenberg, D. F. Easton, N. J. Wareham, S. Burgess, A. Murray, K. K. Ong, T. M. Frayling, J. R. Perry, Using human genetics to understand the disease impacts of testosterone in men and women, Nature Medicine 26 (2) (2020) 252–258. doi:10.1038/s41591-020-0751-5. URL http://www.nature.com/articles/ s41591-020-0751-5
1266 1267 1268 1269 1270 1271	[62]	Y. Guo, S. Warren Andersen, X. O. Shu, K. Michailidou, M. K. Bolla, Q. Wang, M. Garcia-Closas, R. L. Milne, M. K. Schmidt, J. Chang-Claude, A. Dunning, S. E. Bojesen, H. Ahsan, K. Aittomäki, I. L. Andrulis, H. Anton- Culver, V. Arndt, M. W. Beckmann, A. Beeghly-Fadiel, J. Benitez, N. V. Bogdanova, B. Bonanni, A. L. Børresen-Dale, J. Brand, H. Brauch, H. Bren- ner, T. Brüning, B. Burwinkel, G. Casey, G. Chenevix-Trench, F. J. Couch,

A. Cox, S. S. Cross, K. Czene, P. Devilee, T. Dörk, M. Dumont, P. A.

It is made available under a CC-BY 4.0 International license .

Fasching, J. Figueroa, D. Flesch-Janys, O. Fletcher, H. Flyger, F. Fostira, 1273 M. Gammon, G. G. Giles, P. Guénel, C. A. Haiman, U. Hamann, M. J. 1274 Hooning, J. L. Hopper, A. Jakubowska, F. Jasmine, M. Jenkins, E. M. John, 1275 N. Johnson, M. E. Jones, M. Kabisch, M. Kibriya, J. A. Knight, L. B. Kop-1276 pert, V. M. Kosma, V. Kristensen, L. Le Marchand, E. Lee, J. Li, A. Lind-1277 blom, R. Luben, J. Lubinski, K. E. Malone, A. Mannermaa, S. Margolin, 1278 F. Marme, C. McLean, H. Meijers-Heijboer, A. Meindl, S. L. Neuhausen, 1279 H. Nevanlinna, P. Neven, J. E. Olson, J. I. Perez, B. Perkins, P. Peter-1280 longo, K. A. Phillips, K. Pylkäs, A. Rudolph, R. Santella, E. J. Sawyer, 1281 R. K. Schmutzler, C. Seynaeve, M. Shah, M. J. Shrubsole, M. C. Southey, 1282 A. J. Swerdlow, A. E. Toland, I. Tomlinson, D. Torres, T. Truong, G. Ursin, 1283 R. B. Van Der Luijt, S. Verhoef, A. S. Whittemore, R. Winqvist, H. Zhao, 1284 S. Zhao, P. Hall, J. Simard, P. Kraft, P. Pharoah, D. Hunter, D. F. Easton, 1285 W. Zheng, Genetically Predicted Body Mass Index and Breast Cancer Risk: 1286 Mendelian Randomization Analyses of Data from 145,000 Women of Euro-1287 pean Descent, PLoS Medicine 13 (8) (2016) e1002105. doi:10.1371/ 1288 journal.pmed.1002105. 1289 URL http://dx.plos.org/10.1371/journal.pmed.1002105 1290 [63] D. Freuer, J. Linseisen, T. A. O'mara, M. Leitzmann, H. Baurecht, S. E. 1291 Baumeister, C. Meisinger, Body Fat Distribution and Risk of Breast, En-1292 dometrial, and Ovarian Cancer: A Two-Sample Mendelian Randomization 1293 Study, Cancers 13 (20) (10 2021). doi:10.3390/CANCERS13205053. 1294 URL https://pubmed.ncbi.nlm.nih.gov/34680200/ 1295 [64] B. L. Hayes, T. Robinson, S. Kar, K. S. Ruth, K. K. Tsilidis, T. Frayling, 1296 A. Murray, R. M. Martin, D. A. Lawlor, R. C. Richmond, Do sex hormones 1297 confound or mediate the effect of chronotype on breast and prostate cancer? 1298 A Mendelian randomization study, PLoS Genetics 18 (1) (2022) 1-28. 1299 doi:10.1371/journal.pgen.1009887. 1300 URL https://www.ncbi.nlm.nih.gov/pmc/articles/ 1301 PMC8809575 1302 [65] M. Vithayathil, P. Carter, S. Kar, A. M. Mason, S. Burgess, S. C. Larsson, 1303 S. Karx, A. M. Mason, S. Burgess, S. C. Larsson, Body size and compo-1304 sition and site-specific cancers in UK Biobank: a Mendelian randomisation 1305 study, PLoS Medicine 18 (7) (2021) 1-20. doi:10.1101/2020.02.28. 1306 970459. 1307 URL http://dx.doi.org/10.1371/journal.pmed.1003706 1308 [66] N. Dimou, J. Yarmolinsky, E. Bouras, K. K. Tsilidis, R. M. Martin, S. J. 1309

It is made available under a CC-BY 4.0 International license .

Lewis, I. T. Gram, M. F. Bakker, H. Brenner, J. C. Figueiredo, R. T. Fortner, 1310 S. B. Gruber, B. van Guelpen, L. Hsu, R. Kaaks, S. S. Kweon, Y. Lin, N. M. 1311 Lindor, P. A. Newcomb, M. J. Sanchez, G. Severi, H. A. Tindle, R. Tu-1312 mino, E. Weiderpass, M. J. Gunter, N. Murphy, Causal effects of lifetime 1313 smoking on breast and colorectal cancer risk: Mendelian randomization 1314 study, Cancer Epidemiology Biomarkers and Prevention 30 (5) (2021) 1315 953-964. doi:10.1158/1055-9965.EPI-20-1218/71015/AM/ 1316 CAUSAL-EFFECTS-OF-LIFETIME-SMOKING-ON-BREAST-AND. 1317 URL https://aacrjournals.org/cebp/article/30/5/953/ 1318 670780/Causal-Effects-of-Lifetime-Smoking-on-Breast-and 1319 [67] H. A. Park, S. Neumeyer, K. Michailidou, M. K. Bolla, O. Wang, J. Dennis, 1320 T. U. Ahearn, I. L. Andrulis, H. Anton-Culver, N. N. Antonenkova, V. Arndt, 1321 K. J. Aronson, A. Augustinsson, A. Baten, L. E. Beane Freeman, H. Becher, 1322 M. W. Beckmann, S. Behrens, J. Benitez, M. Bermisheva, N. V. Bogdanova, 1323 S. E. Bojesen, H. Brauch, H. Brenner, S. Y. Brucker, B. Burwinkel, D. Campa, 1324 F. Canzian, J. E. Castelao, S. J. Chanock, G. Chenevix-Trench, C. L. Clarke, 1325 A. L. Børresen-Dale, G. I. Grenaker Alnæs, K. K. Sahlberg, L. Ottestad, 1326 R. Kåresen, E. Schlichting, M. M. Holmen, T. Sauer, V. Haakensen, O. En-1327 gebråten, B. Naume, A. Fosså, C. E. Kiserud, K. V. Reinertsen, A. Helland, 1328 M. Riis, J. Geisler, D. M. Conroy, F. J. Couch, A. Cox, S. S. Cross, K. Czene, 1329 M. B. Daly, P. Devilee, T. Dörk, I. dos Santos-Silva, M. Dwek, D. M. Eccles, 1330 A. H. Eliassen, C. Engel, M. Eriksson, D. G. Evans, P. A. Fasching, H. Flyger, 1331 L. Fritschi, M. García-Closas, J. A. García-Sáenz, M. M. Gaudet, G. G. Giles, 1332 G. Glendon, M. S. Goldberg, D. E. Goldgar, A. González-Neira, M. Grip, 1333 P. Guénel, E. Hahnen, C. A. Haiman, N. Håkansson, P. Hall, U. Hamann, 1334 S. Han, E. F. Harkness, S. N. Hart, W. He, B. A. Heemskerk-Gerritsen, J. L. 1335 Hopper, D. J. Hunter, C. Clarke, D. Marsh, R. Scott, R. Baxter, D. Yip, 1336 J. Carpenter, A. Davis, N. Pathmanathan, P. Simpson, D. Graham, M. Sach-1337 chithananthan, D. Amor, L. Andrews, Y. Antill, R. Balleine, J. Beesley, 1338 I. Bennett, M. Bogwitz, L. Botes, M. Brennan, M. Brown, M. Buckley, 1339 J. Burke, P. Butow, L. Caldon, I. Campbell, D. Chauhan, M. Chauhan, 1340 A. Christian, P. Cohen, A. Colley, A. Crook, J. Cui, M. Cummings, S. J. 1341 Dawson, A. DeFazio, M. Delatycki, R. Dickson, J. Dixon, T. Edkins, S. Ed-1342 wards, G. Farshid, A. Fellows, G. Fenton, M. Field, J. Flanagan, P. Fong, 1343 L. Forrest, S. Fox, J. French, M. Friedlander, C. Gaff, M. Gattas, P. George, 1344 S. Greening, M. Harris, S. Hart, N. Hayward, C. Hoskins, C. Hunt, P. James, 1345 M. Jenkins, A. Kidd, J. Kirk, J. Koehler, J. Kollias, S. Lakhani, M. Lawrence, 1346 G. Lindeman, L. Lipton, L. Lobb, G. Mann, D. Marsh, S. A. McLach-1347 lan, B. Meiser, S. Nightingale, S. O'Connell, S. O'Sullivan, D. G. Or-1348

It is made available under a CC-BY 4.0 International license .

tega, N. Pachter, B. Patterson, A. Pearn, K. Phillips, E. Pieper, E. Rickard, 1349 B. Robinson, M. Saleh, E. Salisbury, C. Saunders, J. Saunus, R. Scott, 1350 C. Scott, A. Sexton, A. Shelling, P. Simpson, A. Spurdle, J. Taylor, R. Taylor, 1351 H. Thorne, A. Trainer, K. Tucker, J. Visvader, L. Walker, R. Williams, I. Win-1352 ship, M. A. Young, A. Jager, A. Jakubowska, E. M. John, A. Jung, R. Kaaks, 1353 P. M. Kapoor, R. Keeman, E. Khusnutdinova, C. M. Kitahara, L. B. Kop-1354 pert, S. Koutros, V. N. Kristensen, A. W. Kurian, J. Lacey, D. Lambrechts, 1355 L. Le Marchand, W. Y. Lo, J. Lubiński, A. Mannermaa, M. Manoochehri, 1356 S. Margolin, M. E. Martinez, D. Mavroudis, A. Meindl, U. Menon, R. L. 1357 Milne, T. A. Muranen, H. Nevanlinna, W. G. Newman, B. G. Nordestgaard, 1358 K. Offit, A. F. Olshan, T. W. Park-Simon, P. Peterlongo, J. Peto, D. Plaseska-1359 Karanfilska, P. Radice, G. Rennert, H. S. Rennert, A. Romero, E. Salous-1360 tros, E. J. Sawyer, M. K. Schmidt, R. K. Schmutzler, M. J. Schoemaker, 1361 L. Schwentner, C. Scott, M. Shah, X. O. Shu, J. Simard, A. Smeets, M. C. 1362 Southey, J. J. Spinelli, V. Stevens, A. J. Swerdlow, R. M. Tamimi, W. J. Tap-1363 per, J. A. Taylor, M. B. Terry, I. Tomlinson, M. A. Troester, T. Truong, C. M. 1364 Vachon, E. M. van Veen, J. Vijai, S. Wang, C. Wendt, R. Winqvist, A. Wolk, 1365 A. Ziogas, A. M. Dunning, P. D. Pharoah, D. F. Easton, W. Zheng, P. Kraft, 1366 J. Chang-Claude, Mendelian randomisation study of smoking exposure in 1367 relation to breast cancer risk, British journal of cancer 125 (8) (2021) 1135-1368 1145. doi:10.1038/S41416-021-01432-8. 1369 URL https://pubmed.ncbi.nlm.nih.gov/34341517/ 1370

[68] S. C. Larsson, A. M. Mason, S. Kar, M. Vithayathil, P. Carter, J. A. Baron,
K. Michaëlsson, S. Burgess, Genetically proxied milk consumption and risk
of colorectal, bladder, breast, and prostate cancer: a two-sample Mendelian
randomization study, BMC Medicine 18 (1) (2020) 1–7. doi:10.1186/
S12916-020-01839-9/FIGURES/1.

1376 URL https://bmcmedicine.biomedcentral.com/articles/ 1377 10.1186/s12916-020-01839-9

- [69] A. L. Lumsden, A. Mulugeta, E. Hyppönen, Milk consump-1378 tion and risk of twelve cancers: A large-scale observational and 1379 Mendelian randomisation study, Clinical Nutrition 42 (1) (2023) 1-8. 1380 doi:10.1016/j.clnu.2022.11.006. 1381
- 1382 URL http://www.clinicalnutritionjournal.com/ 1383 article/S0261561422003910/fulltext

^[70] N. Papadimitriou, N. Dimou, K. K. Tsilidis, B. Banbury, R. M. Martin, S. J.
Lewis, N. Kazmi, T. M. Robinson, D. Albanes, K. Aleksandrova, S. I. Berndt,
D. Timothy Bishop, H. Brenner, D. D. Buchanan, B. Bueno-de Mesquita, P. T.

It is made available under a CC-BY 4.0 International license .

Campbell, S. Castellví-Bel, A. T. Chan, J. Chang-Claude, M. Ellingjord-Dale, 1387 J. C. Figueiredo, S. J. Gallinger, G. G. Giles, E. Giovannucci, S. B. Gruber, 1388 A. Gsur, J. Hampe, H. Hampel, S. Harlid, T. A. Harrison, M. Hoffmeister, 1389 J. L. Hopper, L. Hsu, J. María Huerta, J. R. Huyghe, M. A. Jenkins, T. O. 1390 Keku, T. Kühn, C. La Vecchia, L. Le Marchand, C. I. Li, L. Li, A. Lind-1391 blom, N. M. Lindor, B. Lynch, S. D. Markowitz, G. Masala, A. M. May, 1392 R. Milne, E. Monninkhof, L. Moreno, V. Moreno, P. A. Newcomb, K. Of-1393 fit, V. Perduca, P. D. Pharoah, E. A. Platz, J. D. Potter, G. Rennert, E. Ri-1394 boli, M. J. Sánchez, S. L. Schmit, R. E. Schoen, G. Severi, S. Sieri, M. L. 1395 Slattery, M. Song, C. M. Tangen, S. N. Thibodeau, R. C. Travis, A. Tri-1396 chopoulou, C. M. Ulrich, F. J. van Duijnhoven, B. Van Guelpen, P. Vod-1397 icka, E. White, A. Wolk, M. O. Woods, A. H. Wu, U. Peters, M. J. Gunter, 1398 N. Murphy, Physical activity and risks of breast and colorectal cancer: a 1399 Mendelian randomisation analysis, Nature communications 11 (1) (12 2020). 1400 doi:10.1038/S41467-020-14389-8. 1401 URL https://pubmed.ncbi.nlm.nih.gov/32001714/ 1402

[71] H. Li, L. Hou, Y. Yu, X. Sun, X. Liu, Y. Yu, S. Wu, Y. He, Y. Wu, L. He, F. Xue, Lipids, Anthropometric Measures, Smoking and Physical Activity Mediate the Causal Pathway From Education to Breast Cancer in Women: A Mendelian Randomization Study, Journal of Breast Cancer 24 (6) (2021)
504–519. doi:10.4048/jbc.2021.24.e53.

1408 URL https://www.ncbi.nlm.nih.gov/pmc/articles/ 1409 PMC8724372/

[72] Y. Feng, R. Wang, C. Li, X. Cai, Z. Huo, Z. Liu, F. Ge, C. Huang, Y. Lu, R. Zhong, J. Li, B. Cheng, H. Liang, S. Xiong, X. Mao, Y. Chen, R. Lan, Y. Wen, H. Peng, Y. Jiang, Z. Su, X. Wu, J. He, W. Liang, Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study, Translational lung cancer research 11 (7) (2022) 1302–1314. doi:10.21037/ TLCR-22-34.

- 1417 URL https://pubmed.ncbi.nlm.nih.gov/35958335/
- [73] T. Robinson, R. M. Martin, J. Yarmolinsky, Mendelian randomisation analysis of circulating adipokines and C-reactive protein on breast cancer risk, International journal of cancer 147 (6) (2020) 1597–1603. doi:10.1002/ IJC.32947.
- 1422 URL https://pubmed.ncbi.nlm.nih.gov/32134113/
- 1423 [74] E. Bouras, V. Karhunen, D. Gill, J. Huang, P. C. Haycock, M. J. Gunter,

It is made available under a CC-BY 4.0 International license .

M. Johansson, P. Brennan, T. Key, S. J. Lewis, R. M. Martin, N. Mur-1424 phy, E. A. Platz, R. Travis, J. Yarmolinsky, V. Zuber, P. Martin, M. Kat-1425 soulis, H. Freisling, T. H. Nøst, M. B. Schulze, L. Dossus, R. J. Hung, C. I. 1426 Amos, A. Ahola-Olli, S. Palaniswamy, M. Männikkö, J. Auvinen, K. H. 1427 Herzig, S. Keinänen-Kiukaanniemi, T. Lehtimäki, V. Salomaa, O. Raitakari, 1428 M. Salmi, S. Jalkanen, CRUK, CAPS, PEGASUS, M. R. Jarvelin, A. De-1429 hghan, K. K. Tsilidis, Circulating inflammatory cytokines and risk of five 1430 cancers: a Mendelian randomization analysis, BMC Medicine 20 (1) (2022) 1431 1-15. doi:10.1186/s12916-021-02193-0. 1432 URL https://bmcmedicine.biomedcentral.com/articles/ 1433 10.1186/s12916-021-02193-0 1434

[75] J. Yarmolinsky, J. W. Robinson, D. Mariosa, V. Karhunen, J. Huang, N. Di-1435 mou, N. Murphy, K. Burrows, E. Bouras, K. Smith-Byrne, S. J. Lewis, T. E. 1436 Galesloot, L. A. Kiemeney, S. Vermeulen, P. Martin, D. Albanes, L. Hou, 1437 P. A. Newcomb, E. White, A. Wolk, A. H. Wu, L. Le Marchand, A. I. Phipps, 1438 D. D. Buchanan, M. T. Landi, V. Stevens, Y. Wang, D. Albanes, N. Caporaso, 1439 P. Brennan, C. I. Amos, S. Shete, R. J. Hung, H. Bickeböller, A. Risch, 1440 R. Houlston, S. Lam, A. Tardon, C. Chen, S. E. Bojesen, M. Johansson, H. E. 1441 Wichmann, D. Christiani, G. Rennert, S. Arnold, J. K. Field, L. Le Marchand, 1442 O. Melander, H. Brunnström, G. Liu, A. Andrew, H. Shen, S. Zienolddiny, 1443 K. Grankvist, M. Johansson, M. D. Teare, Y. C. Hong, J. M. Yuan, P. Lazarus, 1444 M. B. Schabath, M. C. Aldrich, R. A. Eeles, C. A. Haiman, Z. Kote-Jarai, 1445 F. R. Schumacher, S. Benlloch, A. A. Al Olama, K. R. Muir, S. I. Berndt, 1446 D. V. Conti, F. Wiklund, S. Chanock, C. M. Tangen, J. Batra, J. A. Clements, 1447 H. Grönberg, N. Pashayan, J. Schleutker, S. J. Weinstein, C. M. West, L. A. 1448 Mucci, G. Cancel-Tassin, S. Koutros, K. D. Sørensen, E. M. Grindedal, 1449 D. E. Neal, F. C. Hamdy, J. L. Donovan, R. C. Travis, R. J. Hamilton, S. A. 1450 Ingles, B. S. Rosenstein, Y. J. Lu, G. G. Giles, R. J. MacInnis, A. S. Kibel, 1451 A. Vega, M. Kogevinas, K. L. Penney, J. Y. Park, J. L. Stanfrod, C. Cybulski, 1452 B. G. Nordestgaard, S. F. Nielsen, H. Brenner, C. Maier, C. J. Logothetis, 1453 E. M. John, M. R. Teixeira, S. L. Neuhausen, K. De Ruyck, A. Razack, L. F. 1454 Newcomb, D. Lessel, R. Kaneva, N. Usmani, F. Claessens, P. A. Townsend, 1455 J. E. Castelao, M. J. Roobol, F. Menegaux, K. T. Khaw, L. Cannon-Albright, 1456 H. Pandha, S. N. Thibodeau, D. J. Hunter, P. Kraft, W. J. Blot, E. Riboli, 1457 S. S. Zhao, D. Gill, S. J. Chanock, M. P. Purdue, G. Davey Smith, K. H. 1458 Herzig, M. R. Järvelin, C. I. Amos, A. Dehghan, M. J. Gunter, K. K. Tsilidis, 1459 R. M. Martin, Association between circulating inflammatory markers and 1460 adult cancer risk: a Mendelian randomization analysis, eBioMedicine 100 1461 (2 2024). doi:10.1016/J.EBIOM.2024.104991/ATTACHMENT/ 1462

It is made available under a CC-BY 4.0 International license .

0C4432FD-1E6E-480A-A8CA-D4C73CF8C81C/MMC2.DOCX. 1463 URL http://www.thelancet.com/article/ 1464 S2352396424000264/fulltext 1465 [76] Z. Zhao, Q. Cao, M. Zhu, C. Wang, X. Lu, Causal relationships between 1466 serum matrix metalloproteinases and estrogen receptor-negative breast 1467 cancer: a bidirectional mendelian randomization study, Scientific Reports 1468 2023 13:1 13 (1) (2023) 1-25. doi:10.1038/s41598-023-34200-0. 1469 URL https://www.nature.com/articles/ 1470 s41598-023-34200-0 1471 [77] X. Shu, L. Wu, N. K. Khankari, X. O. Shu, T. J. Wang, K. Michailidou, 1472 M. K. Bolla, Q. Wang, J. Dennis, R. L. Milne, M. K. Schmidt, P. D. Pharoah, 1473 I. L. Andrulis, D. J. Hunter, J. Simard, D. F. Easton, W. Zheng, Associations 1474 of obesity and circulating insulin and glucose with breast cancer risk: A 1475 Mendelian randomization analysis, International Journal of Epidemiology 1476 48 (3) (2019) 795-806. doi:10.1093/ije/dyy201. 1477 URL http://ccge.medschl.cam.ac.uk/research/ 1478 consortia/ 1479 [78] K. Smith-Byrne, A. Hedman, M. Dimitriou, T. Desai, A. V. Sokolov, H. B. 1480 Schioth, M. Koprulu, M. Pietzner, C. Langenberg, J. Atkins, R. Cortez, 1481 J. McKay, P. Brennan, S. Zhou, B. J. Richards, J. Yarmolinsky, R. M. 1482 Martin, J. Borlido, X. J. Mu, A. Butterworth, X. Shen, J. Wilson, T. L. 1483 Assimes, R. J. Hung, C. Amos, M. Purdue, N. Rothman, S. Chanock, 1484 R. C. Travis, M. Johansson, A. Mälarstig, Identifying therapeutic targets for 1485 cancer: 2,094 circulating proteins and risk of nine cancers, medRxiv (2023) 1486 2023.05.05.23289547doi:10.1101/2023.05.05.23289547. 1487 URL https://www.medrxiv.org/content/10.1101/2023. 1488 05.05.23289547v1 1489 [79] F. Chen, W. Wen, J. Long, X. Shu, Y. Yang, X. Shu, W. Zheng, Mendelian 1490 randomization analyses of 23 known and suspected risk factors and biomark-1491 ers for breast cancer overall and by molecular subtypes, International Journal 1492 of Cancer (4 2022). doi:10.1002/IJC.34026. 1493 https://onlinelibrary.wiley.com/doi/10.1002/ URL 1494 ijc.34026 1495 [80] M. Escala-Garcia, A. Morra, S. Canisius, J. Chang-Claude, S. Kar, W. Zheng, 1496 S. E. Bojesen, D. Easton, P. D. P. Pharoah, M. K. Schmidt, Breast cancer risk 1497 factors and their effects on survival: a Mendelian randomisation study, BMC 1498

It is made available under a CC-BY 4.0 International license .

Medicine 18 (1) (2020) 1-10. doi:10.1186/s12916-020-01797-2. 1499 URL https://doi.org/10.1186/s12916-020-01797-2 1500 [81] D. A. Lawlor, Commentary: Two-sample Mendelian randomization: Oppor-1501 tunities and challenges, International Journal of Epidemiology 45 (3) (2016) 1502 908-915. doi:10.1093/ije/dyw127. 1503 https://www.ncbi.nlm.nih.gov/pmc/articles/ URL 1504 PMC5005949/ 1505 [82] M. R. Munafo, J. Brown, M. Hefler, G. Davey Smith, Man-1506 aging the exponential growth of mendelian randomization stud-1507 ies, Tobacco Control 33 (5) (2024) 559-560. arXiv:https: 1508 //tobaccocontrol.bmj.com/content/33/5/559.full.pdf, 1509 doi:10.1136/tc-2024-058987. 1510 URL https://tobaccocontrol.bmj.com/content/33/5/559 1511 [83] G. D. Smith, S. Ebrahim, Mendelian randomisation at 20 years: how can it 1512 avoid hubris, while achieving more?, The Lancet Diabetes and Endocrinology 1513 8587 (23) (2023) 10-12. doi:10.1016/S2213-8587 (23) 00348-0. 1514 URL https://doi.org/10.1016/S2213-8587(23)00348-0 1515 [84] S. Stender, H. Gellert-Kristensen, G. D. Smith, Reclaiming mendelian 1516 randomization from the deluge of papers and misleading findings, 1517 Lipids in Health and Disease 23 (1) (2024) 286. doi:10.1186/ 1518 s12944-024-02284-w. 1519 URL https://doi.org/10.1186/s12944-024-02284-w 1520 [85] A. Buniello, J. A. Macarthur, M. Cerezo, L. W. Harris, J. Hayhurst, 1521 C. Malangone, A. McMahon, J. Morales, E. Mountjoy, E. Sollis, D. Su-1522 veges, O. Vrousgou, P. L. Whetzel, R. Amode, J. A. Guillen, H. S. Riat, 1523 S. J. Trevanion, P. Hall, H. Junkins, P. Flicek, T. Burdett, L. A. Hindorff, 1524 F. Cunningham, H. Parkinson, The NHGRI-EBI GWAS Catalog of pub-1525 lished genome-wide association studies, targeted arrays and summary statis-1526 tics 2019, Nucleic Acids Research 47 (D1) (2019) D1005-D1012. doi: 1527 10.1093/nar/gkv1120. 1528 URL https://pubmed.ncbi.nlm.nih.gov/30445434/ 1529 [86] B. B. Sun, J. Chiou, M. Traylor, C. Benner, Y. H. Hsu, T. G. Richardson, 1530 P. Surendran, A. Mahajan, C. Robins, S. G. Vasquez-Grinnell, L. Hou, E. M. 1531 Kvikstad, O. S. Burren, J. Davitte, K. L. Ferber, C. E. Gillies, A. K. Hed-1532 man, S. Hu, T. Lin, R. Mikkilineni, R. K. Pendergrass, C. Pickering, B. Prins, 1533 D. Baird, C. Y. Chen, L. D. Ward, A. M. Deaton, S. Welsh, C. M. Willis, 1534

It is made available under a CC-BY 4.0 International license .

N. Lehner, M. Arnold, M. A. Wörheide, K. Suhre, G. Kastenmüller, A. Sethi, 1535 M. Cule, A. Raj, H. M. Kang, L. Burkitt-Gray, E. Melamud, M. H. Black, 1536 E. B. Fauman, J. M. Howson, H. M. Kang, M. I. McCarthy, P. Nioi, S. Petro-1537 vski, R. A. Scott, E. N. Smith, S. Szalma, D. M. Waterworth, L. J. Mit-1538 naul, J. D. Szustakowski, B. W. Gibson, M. R. Miller, C. D. Whelan, Plasma 1539 proteomic associations with genetics and health in the UK Biobank, Nature 1540 622 (7982) (2023) 329-338. doi:10.1038/S41586-023-06592-6. 1541 URL https://pubmed.ncbi.nlm.nih.gov/37794186/ 1542 [87] H. Julkunen, A. Cichońska, M. Tiainen, H. Koskela, K. Nybo, V. Mäkelä, 1543 J. Nokso-Koivisto, K. Kristiansson, M. Perola, V. Salomaa, P. Jousilahti, 1544 A. Lundqvist, A. J. Kangas, P. Soininen, J. C. Barrett, P. Würtz, Atlas 1545 of plasma NMR biomarkers for health and disease in 118,461 individ-1546 uals from the UK Biobank, Nature Communications 14 (1) (12 2023). 1547 doi:10.1038/S41467-023-36231-7. 1548 URL https://www.ncbi.nlm.nih.gov/pmc/articles/ 1549 PMC9898515/ 1550 [88] E. Moreau, Literature-based discovery: Addressing the issue of the 1551 subpar evaluation methodology, Bioinformatics 39 (2) (2023) 1-3. 1552 doi:10.1093/bioinformatics/btad090. 1553 https://www.ncbi.nlm.nih.gov/pmc/articles/ URL 1554 PMC9945845/ 1555 [89] E. Moreau, O. Hardiman, M. Heverin, D. O'Sullivan, Mining impactful dis-1556 coveries from the biomedical literature, bioRxiv (2022) 2022.10.28.514184. 1557 https://www.biorxiv.org/content/10.1101/2022. URL 1558 10.28.514184v1 1559 [90] O. Bodenreider, The Unified Medical Language System (UMLS): Integrating 1560 biomedical terminology, Nucleic Acids Research 32 (DATABASE ISS.) 1561 (2004) 267-270. doi:10.1093/nar/gkh061. 1562 URL https://www.ncbi.nlm.nih.gov/pmc/articles/ 1563 PMC308795/ 1564 [91] K. H. Wade, J. Yarmolinsky, E. Giovannucci, S. J. Lewis, I. Y. Millwood, 1565 M. R. Munafò, F. Meddens, K. Burrows, J. A. Bell, N. M. Davies, D. Mar-1566 iosa, N. Kanerva, E. E. Vincent, K. Smith-Byrne, F. Guida, M. J. Gunter, 1567 E. Sanderson, F. Dudbridge, S. Burgess, M. C. Cornelis, T. G. Richardson, 1568 M. C. Borges, J. Bowden, G. Hemani, Y. Cho, W. Spiller, R. C. Richmond, 1569 A. R. Carter, R. Langdon, D. A. Lawlor, R. G. Walters, K. S. Vimaleswaran, 1570 A. Anderson, M. R. Sandu, K. Tilling, G. Davey Smith, R. M. Martin, C. L. 1571

It is made available under a CC-BY 4.0 International license .

Relton, Applying Mendelian randomization to appraise causality in relation-1572 ships between nutrition and cancer, Cancer Causes & Control 33 (2022). 1573 doi:10.1007/s10552-022-01562-1. 1574 URL https://doi.org/10.1007/s10552-022-01562-1 1575 [92] P. C. Haycock, S. Burgess, K. H. Wade, J. Bowden, C. Relton, G. D. Smith, 1576 Best (but oft-forgotten) practices: the design, analysis, and interpretation of 1577 Mendelian randomization studies (4 2016). doi:10.3945/ajcn.115. 1578 118216. 1579 URL https://pubmed.ncbi.nlm.nih.gov/26961927/ 1580 [93] M. C. Cornelis, T. Kacprowski, C. Menni, S. Gustafsson, E. Pivin, 1581 J. Adamski, A. Artati, C. B. Eap, G. Ehret, N. Friedrich, A. Ganna, I. Gues-1582 sous, G. Homuth, L. Lind, P. K. Magnusson, M. Mangino, N. L. Pedersen, 1583 M. Pietzner, K. Suhre, H. Völzke, M. Bochud, T. D. Spector, H. J. Grabe, 1584 E. Ingelsson, M. Burnier, O. Devuyst, P. Y. Martin, M. Mohaupt, F. Paccaud, 1585 A. Pechere-Bertschi, B. Vogt, D. Ackermann, B. Ponte, M. Pruijm, Genome-1586 wide association study of caffeine metabolites provides new insights to caf-1587 feine metabolism and dietary caffeine-consumption behavior, Human molec-1588 ular genetics 25 (24) (2016) 5472-5482. doi:10.1093/HMG/DDW334. 1589 URL https://pubmed.ncbi.nlm.nih.gov/27702941/ 1590 [94] S. E. Steck, E. A. Murphy, Dietary patterns and cancer risk, Nature Reviews 1591 Cancer 20 (2) (2020) 125-138. doi:10.1038/s41568-019-0227-4. 1592 URL http://dx.doi.org/10.1038/s41568-019-0227-4 1593 [95] N. I. Pirastu, C. McDonnell, E. J. Grzeszkowiak ID, N. I. Mounier, F. Imamu-1594 raID, J. MerinoID, F. R. DayID, J. ZhengID, N. TabaID, M. Pina ConcasID, 1595 L. RepettoID, K. A. KentistouID, A. RobinoID, T. EskoID, P. K. JoshiID, 1596 K. FischerID, K. K. OngID, T. R. GauntID, Z. Kutalik, J. R. B Perry, J. F. 1597 WilsonID, Using genetic variation to disentangle the complex relationship 1598 between food intake and health outcomes, PLOS Genetics 18 (6) (2022) 1599 e1010162. doi:10.1371/JOURNAL.PGEN.1010162. 1600 URL https://journals.plos.org/plosgenetics/article? 1601 id=10.1371/journal.pgen.1010162 1602 [96] C. Jin, R. Li, T. Deng, Z. Lin, H. Li, Y. Yang, Q. Su, J. Wang, Y. Yang, 1603 J. Wang, G. Chen, Y. Wang, Association between dried fruit intake and 1604 pan-cancers incidence risk: A two-sample Mendelian randomization study, 1605 Frontiers in Nutrition 9 (July) (2022) 1-14. doi:10.3389/fnut.2022. 1606 899137. 1607 URL https://pubmed.ncbi.nlm.nih.gov/30696460/ 1608

It is made available under a CC-BY 4.0 International license .

1609	[97]	H. K. Neilson, M. S. Farris, C. R. Stone, M. M. Vaska, D. R. Brenner, C. M.
1610		Friedenreich, Moderate-vigorous recreational physical activity and breast
1611		cancer risk, stratified by menopause status: A systematic review and meta-
1612		analysis (10 2016). doi:10.1097/GME.000000000000745.
1613		URL https://pubmed.ncbi.nlm.nih.gov/27779567/
1614	[98]	F. Chong, Y. Wang, M. Song, Q. Sun, W. Xie, C. Song, Sedentary behavior
1614 1615	[98]	F. Chong, Y. Wang, M. Song, Q. Sun, W. Xie, C. Song, Sedentary behavior and risk of breast cancer: a dose-response meta-analysis from prospective
1614 1615 1616	[98]	F. Chong, Y. Wang, M. Song, Q. Sun, W. Xie, C. Song, Sedentary behavior and risk of breast cancer: a dose-response meta-analysis from prospective studies, Breast cancer (Tokyo, Japan) 28 (1) (2021) 48–59. doi:10.1007/
1614 1615 1616 1617	[98]	F. Chong, Y. Wang, M. Song, Q. Sun, W. Xie, C. Song, Sedentary behavior and risk of breast cancer: a dose-response meta-analysis from prospective studies, Breast cancer (Tokyo, Japan) 28 (1) (2021) 48–59. doi:10.1007/S12282-020-01126-8.